Lopinavir

Identification

Name

Lopinavir

Accession Number

DB01601  (EXPT00388)

Type

Small Molecule

Groups

Approved

Description

Lopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. It is marketed by Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS.

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for DB01601 (Lopinavir)

×

Close

Synonyms

• LPV

External IDs

A-157378-0 / A-157378.0 / ABT-378

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Kaletra	Lopinavir (200 mg/1) + Ritonavir (50 mg/1)	Tablet, film coated	Oral	Physicians Total Care, Inc.	2006-04-11	Not applicable
Kaletra	Lopinavir (200 mg) + Ritonavir (50 mg)	Tablet	Oral	Abbvie	2006-09-08	Not applicable
Kaletra	Lopinavir (100 mg/1) + Ritonavir (25 mg/1)	Tablet, film coated	Oral	Abbvie	2010-06-18	Not applicable
Kaletra	Lopinavir (200 mg/1) + Ritonavir (50 mg/1)	Tablet, film coated	Oral	Remedy Repack	2008-06-09	2017-01-18
Kaletra	Lopinavir (200 mg/1) + Ritonavir (50 mg/1)	Tablet, film coated	Oral	Abbvie	2010-06-18	Not applicable
Kaletra	Lopinavir (200 mg/1) + Ritonavir (50 mg/1)	Tablet, film coated	Oral	Dispensing Solutions, Inc.	2010-06-18	Not applicable
Kaletra	Lopinavir (133.3 mg) + Ritonavir (33.3 mg)	Capsule	Oral	Abbvie	2001-03-09	2012-11-02
Kaletra	Lopinavir (200 mg/1) + Ritonavir (50 mg/1)	Tablet, film coated	Oral	Doh Central Pharmacy	2009-07-01	Not applicable
Kaletra	Lopinavir (200 mg/1) + Ritonavir (50 mg/1)	Tablet, film coated	Oral	Rebel Distributors	2010-06-18	Not applicable
Kaletra	Lopinavir (80 mg) + Ritonavir (20 mg)	Solution	Oral	Abbvie	2001-03-09	Not applicable

International/Other Brands

Aluviran / Koletra

Categories

• Anti-HIV Agents
• Anti-Infective Agents
• Anti-Retroviral Agents
• Antiinfectives for Systemic Use
• Antiviral Agents
• Antivirals for Systemic Use
• BSEP/ABCB11 Substrates
• Chemically-Induced Disorders
• Combined Inhibitors of CYP3A4 and P-glycoprotein (Strong)
• CYP3A Substrates (Sensitive)
• Cytochrome P-450 CYP2B6 Inhibitors
• Cytochrome P-450 CYP2B6 Inhibitors (weak)
• Cytochrome P-450 CYP2C19 Inhibitors
• Cytochrome P-450 CYP2C19 Inhibitors (weak)
• Cytochrome P-450 CYP2C8 Inhibitors
• Cytochrome P-450 CYP2C8 Inhibitors (strong)
• Cytochrome P-450 CYP2C9 Inhibitors
• Cytochrome P-450 CYP2C9 Inhibitors (weak)
• Cytochrome P-450 CYP2D6 Inhibitors
• Cytochrome P-450 CYP2D6 Inhibitors (moderate)
• Cytochrome P-450 CYP3A Inhibitors
• Cytochrome P-450 CYP3A Inhibitors (strong)
• Cytochrome P-450 CYP3A Substrates
• Cytochrome P-450 CYP3A4 Inhibitors
• Cytochrome P-450 CYP3A4 Inhibitors (strong)
• Cytochrome P-450 CYP3A4 Substrates
• Cytochrome P-450 CYP3A4 Substrates (strength unknown)
• Cytochrome P-450 Enzyme Inducers
• Cytochrome P-450 Enzyme Inhibitors
• Direct Acting Antivirals
• Enzyme Inhibitors
• Highest Risk QTc-Prolonging Agents
• HIV Protease Inhibitors
• Hyperglycemia-Associated Agents
• OATP1B1/SLCO1B1 Inhibitors
• OATP1B3 transporter inhibitors
• P-glycoprotein/ABCB1 Inhibitors
• Protease Inhibitors
• Pyrimidines
• Pyrimidinones
• QTc Prolonging Agents

UNII

2494G1JF75

CAS number

192725-17-0

Weight

Average: 628.8008
Monoisotopic: 628.362470666

Chemical Formula

C₃₇H₄₈N₄O₅

InChI Key

KJHKTHWMRKYKJE-SUGCFTRWSA-N

InChI

InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1

IUPAC Name

(2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide

SMILES

CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1

Pharmacology

Indication

Indicated in combination with other antiretroviral agents for the treatment of HIV-infection.

Associated Conditions

• Infection, Human Immunodeficiency Virus I

Pharmacodynamics

Lopinavir is an antiretroviral of the protease inhibitor class. Inhibiting HIV-1 protease (responsible for protein cleavage), results in selectively inhibiting the cleavage of HIV gag and gag-pol polyproteins, thereby preventing viral maturation.

Mechanism of action

Lopinavir inhibits the HIV viral protease enzyme. This prevents cleavage of the gag-pol polyprotein and, therefore, improper viral assembly results. This subsequently results in non-infectious, immature viral particles.

Target	Actions	Organism
AHuman immunodeficiency virus type 1 protease	inhibitor	Human immunodeficiency virus 1

Absorption

Administered alone, lopinavir has insufficient bioavailability; however, like several HIV protease inhibitors, its blood levels are greatly increased by low doses of ritonavir, a potent inhibitor of cytochrome P450 3A4.

Volume of distribution

Not Available

Protein binding

Lopinavir is highly bound to plasma proteins (98-99%).

Metabolism

Hepatic. Lopinavir is extensively metabolized by the hepatic cytochrome P450 system, almost exclusively by the CYP3A isozyme.

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Although human experience of acute overdosage with lopinavir is limited, accidental ingestion of the product by a young child could result in significant alcohol-related toxicity and could approach the potential lethal dose of alcohol.

Affected organisms

• Human Immunodeficiency Virus

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE	The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Lopinavir.	Experimental
16-Bromoepiandrosterone	The serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Lopinavir.	Investigational
19-norandrostenedione	The serum concentration of 19-norandrostenedione can be increased when it is combined with Lopinavir.	Experimental, Illicit
2,4-thiazolidinedione	The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Lopinavir.	Investigational
4-Methoxyamphetamine	The metabolism of 4-Methoxyamphetamine can be decreased when combined with Lopinavir.	Experimental, Illicit
5-androstenedione	The serum concentration of 5-androstenedione can be increased when it is combined with Lopinavir.	Experimental, Illicit
Abacavir	The serum concentration of Abacavir can be decreased when it is combined with Lopinavir.	Approved, Investigational
Abemaciclib	The risk or severity of adverse effects can be increased when Lopinavir is combined with Abemaciclib.	Approved, Investigational
Abiraterone	The metabolism of Abiraterone can be decreased when combined with Lopinavir.	Approved
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Lopinavir.	Approved, Investigational
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Lopinavir.	Approved, Investigational
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Lopinavir.	Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lopinavir.	Approved, Investigational, Withdrawn
Acetyl sulfisoxazole	The metabolism of Lopinavir can be decreased when combined with Acetyl sulfisoxazole.	Approved, Vet Approved
Acetylcholine	The metabolism of Acetylcholine can be decreased when combined with Lopinavir.	Approved
Adinazolam	The metabolism of Adinazolam can be decreased when combined with Lopinavir.	Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Lopinavir.	Approved
Agmatine	The metabolism of Agmatine can be decreased when combined with Lopinavir.	Experimental, Investigational
AICA ribonucleotide	The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Lopinavir.	Experimental, Investigational
Ajmaline	The metabolism of Ajmaline can be decreased when combined with Lopinavir.	Approved, Investigational
Albendazole	The metabolism of Albendazole can be decreased when combined with Lopinavir.	Approved, Vet Approved
Alclometasone	The metabolism of Alclometasone can be decreased when combined with Lopinavir.	Approved
Aldosterone	The serum concentration of Aldosterone can be increased when it is combined with Lopinavir.	Experimental, Investigational
Alfentanil	The metabolism of Alfentanil can be decreased when combined with Lopinavir.	Approved, Illicit
Alfuzosin	The serum concentration of Alfuzosin can be increased when it is combined with Lopinavir.	Approved, Investigational
Aliskiren	The metabolism of Aliskiren can be decreased when combined with Lopinavir.	Approved, Investigational
Allicin	The therapeutic efficacy of Allicin can be decreased when used in combination with Lopinavir.	Investigational
Allylestrenol	The metabolism of Allylestrenol can be decreased when combined with Lopinavir.	Approved
Almotriptan	The serum concentration of Almotriptan can be increased when it is combined with Lopinavir.	Approved, Investigational
Alogliptin	The metabolism of Alogliptin can be decreased when combined with Lopinavir.	Approved
Alosetron	The serum concentration of Alosetron can be increased when it is combined with Lopinavir.	Approved, Withdrawn
alpha-Tocopherol acetate	The metabolism of alpha-Tocopherol acetate can be decreased when combined with Lopinavir.	Approved
Alprazolam	The serum concentration of Alprazolam can be increased when it is combined with Lopinavir.	Approved, Illicit, Investigational
Alprenolol	The metabolism of Alprenolol can be decreased when combined with Lopinavir.	Approved, Withdrawn
Amantadine	Amantadine may increase the QTc-prolonging activities of Lopinavir.	Approved
Ambrisentan	The metabolism of Ambrisentan can be decreased when combined with Lopinavir.	Approved, Investigational
Ambroxol	The metabolism of Ambroxol can be decreased when combined with Lopinavir.	Approved, Investigational
Ambroxol acefyllinate	The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Lopinavir.	Experimental, Investigational
Amcinonide	The serum concentration of Amcinonide can be increased when it is combined with Lopinavir.	Approved
Amineptine	The serum concentration of Amineptine can be increased when it is combined with Lopinavir.	Illicit, Withdrawn
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Lopinavir.	Approved, Withdrawn
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Lopinavir.	Approved
Amiodarone	The serum concentration of Amiodarone can be increased when it is combined with Lopinavir.	Approved, Investigational
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Lopinavir.	Approved
Amitriptylinoxide	The serum concentration of Amitriptylinoxide can be increased when it is combined with Lopinavir.	Approved, Investigational
Amlodipine	The metabolism of Amlodipine can be decreased when combined with Lopinavir.	Approved
Amodiaquine	The serum concentration of Amodiaquine can be increased when it is combined with Lopinavir.	Approved, Investigational
Amoxapine	The metabolism of Amoxapine can be decreased when combined with Lopinavir.	Approved
Amoxicillin	The metabolism of Amoxicillin can be increased when combined with Lopinavir.	Approved, Vet Approved
Amphetamine	The metabolism of Amphetamine can be decreased when combined with Lopinavir.	Approved, Illicit, Investigational
Amprenavir	The metabolism of Amprenavir can be decreased when combined with Lopinavir.	Approved, Investigational
Amsacrine	The metabolism of Amsacrine can be decreased when combined with Lopinavir.	Approved, Investigational
Anagrelide	The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Lopinavir.	Approved
Androstenedione	The serum concentration of Androstenedione can be increased when it is combined with Lopinavir.	Experimental, Illicit
Anecortave	The serum concentration of Anecortave can be increased when it is combined with Lopinavir.	Investigational
anecortave acetate	The serum concentration of anecortave acetate can be increased when it is combined with Lopinavir.	Investigational
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Lopinavir.	Approved, Investigational
Apalutamide	The serum concentration of Apalutamide can be increased when it is combined with Lopinavir.	Approved, Investigational
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Lopinavir.	Approved
Apomorphine	Apomorphine may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Apremilast	The metabolism of Apremilast can be decreased when combined with Lopinavir.	Approved, Investigational
Aprepitant	The serum concentration of Lopinavir can be increased when it is combined with Aprepitant.	Approved, Investigational
Aprindine	The metabolism of Aprindine can be decreased when combined with Lopinavir.	Approved
Aranidipine	The metabolism of Aranidipine can be decreased when combined with Lopinavir.	Approved, Investigational
Arformoterol	The metabolism of Arformoterol can be decreased when combined with Lopinavir.	Approved, Investigational
Argatroban	The metabolism of Argatroban can be decreased when combined with Lopinavir.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be increased when it is combined with Lopinavir.	Approved, Investigational
Arsenic trioxide	The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Lopinavir.	Approved, Investigational
Artemether	The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Artemether.	Approved
Asenapine	The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Asenapine.	Approved
Astemizole	The serum concentration of Astemizole can be increased when it is combined with Lopinavir.	Approved, Withdrawn
Asunaprevir	The serum concentration of Asunaprevir can be decreased when it is combined with Lopinavir.	Approved, Investigational, Withdrawn
Atamestane	The serum concentration of Atamestane can be increased when it is combined with Lopinavir.	Investigational
Atazanavir	The metabolism of Lopinavir can be decreased when combined with Atazanavir.	Approved, Investigational
Atomoxetine	The serum concentration of Atomoxetine can be increased when it is combined with Lopinavir.	Approved
Atorvastatin	The risk or severity of adverse effects can be increased when Lopinavir is combined with Atorvastatin.	Approved
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Lopinavir.	Approved
Avatrombopag	The metabolism of Avatrombopag can be decreased when combined with Lopinavir.	Approved, Investigational
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Lopinavir.	Approved, Investigational
Azelastine	The metabolism of Azelastine can be decreased when combined with Lopinavir.	Approved
Azelnidipine	The metabolism of Azelnidipine can be decreased when combined with Lopinavir.	Approved, Investigational
Azithromycin	Azithromycin may increase the QTc-prolonging activities of Lopinavir.	Approved
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Lopinavir.	Investigational
Banoxantrone	The metabolism of Banoxantrone can be decreased when combined with Lopinavir.	Investigational
Baricitinib	The metabolism of Baricitinib can be decreased when combined with Lopinavir.	Approved, Investigational
Barnidipine	The serum concentration of Barnidipine can be increased when it is combined with Lopinavir.	Approved
Beclomethasone dipropionate	The metabolism of Beclomethasone dipropionate can be decreased when combined with Lopinavir.	Approved, Investigational
Bedaquiline	The serum concentration of Bedaquiline can be increased when it is combined with Lopinavir.	Approved
Bempedoic acid	The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Lopinavir.	Investigational
Bencyclane	The metabolism of Bencyclane can be decreased when combined with Lopinavir.	Experimental
Benidipine	The metabolism of Benidipine can be decreased when combined with Lopinavir.	Approved, Investigational
Benzatropine	The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Lopinavir.	Approved
Benzphetamine	The metabolism of Benzphetamine can be decreased when combined with Lopinavir.	Approved, Illicit
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Lopinavir.	Approved
Bepridil	The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Bepridil.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Lopinavir.	Approved, Vet Approved
Betaxolol	The metabolism of Betaxolol can be decreased when combined with Lopinavir.	Approved, Investigational
Bexarotene	The metabolism of Bexarotene can be decreased when combined with Lopinavir.	Approved, Investigational
Bezafibrate	The metabolism of Bezafibrate can be decreased when combined with Lopinavir.	Approved, Investigational
Bicalutamide	The metabolism of Bicalutamide can be decreased when combined with Lopinavir.	Approved
Bictegravir	The metabolism of Bictegravir can be decreased when combined with Lopinavir.	Approved, Investigational
Bioallethrin	The metabolism of Bioallethrin can be decreased when combined with Lopinavir.	Approved, Experimental
Bisoprolol	The metabolism of Bisoprolol can be decreased when combined with Lopinavir.	Approved
Blonanserin	The metabolism of Blonanserin can be decreased when combined with Lopinavir.	Approved, Investigational
Boceprevir	The serum concentration of Lopinavir can be decreased when it is combined with Boceprevir.	Approved, Withdrawn
Bortezomib	The serum concentration of Bortezomib can be increased when it is combined with Lopinavir.	Approved, Investigational
Bosentan	The serum concentration of Bosentan can be increased when it is combined with Lopinavir.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Lopinavir.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Lopinavir.	Approved, Investigational
Brexpiprazole	The serum concentration of Brexpiprazole can be increased when it is combined with Lopinavir.	Approved, Investigational
Brigatinib	The serum concentration of Brigatinib can be increased when it is combined with Lopinavir.	Approved, Investigational
Brinzolamide	The serum concentration of Brinzolamide can be increased when it is combined with Lopinavir.	Approved
Brivaracetam	The metabolism of Brivaracetam can be decreased when combined with Lopinavir.	Approved, Investigational
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Lopinavir.	Approved, Illicit, Investigational
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lopinavir.	Approved, Investigational
Brompheniramine	The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Lopinavir.	Approved
Budesonide	The serum concentration of Budesonide can be increased when it is combined with Lopinavir.	Approved
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Lopinavir.	Investigational, Withdrawn
Bufuralol	The metabolism of Bufuralol can be decreased when combined with Lopinavir.	Experimental, Investigational
Bupivacaine	The metabolism of Bupivacaine can be decreased when combined with Lopinavir.	Approved, Investigational
Buprenorphine	The metabolism of Buprenorphine can be decreased when combined with Lopinavir.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The serum concentration of Bupropion can be decreased when it is combined with Lopinavir.	Approved
Buserelin	Buserelin may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Buspirone	The metabolism of Buspirone can be decreased when combined with Lopinavir.	Approved, Investigational
Busulfan	The metabolism of Busulfan can be decreased when combined with Lopinavir.	Approved, Investigational
Butriptyline	The serum concentration of Butriptyline can be increased when it is combined with Lopinavir.	Approved
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Lopinavir.	Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Lopinavir.	Approved
Cabozantinib	The serum concentration of Cabozantinib can be increased when it is combined with Lopinavir.	Approved, Investigational
Caffeine	The metabolism of Caffeine can be decreased when combined with Lopinavir.	Approved
Calcitriol	The metabolism of Calcitriol can be decreased when combined with Lopinavir.	Approved, Nutraceutical
Canagliflozin	The metabolism of Canagliflozin can be decreased when combined with Lopinavir.	Approved
Cannabidiol	The metabolism of Cannabidiol can be decreased when combined with Lopinavir.	Approved, Investigational
Captopril	The metabolism of Captopril can be decreased when combined with Lopinavir.	Approved
Carbamazepine	The serum concentration of Lopinavir can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The metabolism of Carbinoxamine can be decreased when combined with Lopinavir.	Approved
Carboxyamidotriazole	The metabolism of Carboxyamidotriazole can be decreased when combined with Lopinavir.	Investigational
Carbutamide	The therapeutic efficacy of Carbutamide can be decreased when used in combination with Lopinavir.	Experimental
Cariprazine	The metabolism of Cariprazine can be decreased when combined with Lopinavir.	Approved, Investigational
Carisoprodol	The metabolism of Carisoprodol can be increased when combined with Lopinavir.	Approved
Caroverine	The metabolism of Caroverine can be decreased when combined with Lopinavir.	Experimental
Carteolol	The metabolism of Carteolol can be decreased when combined with Lopinavir.	Approved
Carvedilol	The metabolism of Carvedilol can be decreased when combined with Lopinavir.	Approved, Investigational
Castanospermine	The therapeutic efficacy of Castanospermine can be decreased when used in combination with Lopinavir.	Experimental
Celecoxib	The metabolism of Celecoxib can be decreased when combined with Lopinavir.	Approved, Investigational
Celiprolol	The metabolism of Celiprolol can be decreased when combined with Lopinavir.	Approved, Investigational
Cephalexin	The metabolism of Cephalexin can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Lopinavir.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Lopinavir.	Approved, Withdrawn
Cetirizine	The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Lopinavir.	Approved
Cevimeline	The metabolism of Cevimeline can be decreased when combined with Lopinavir.	Approved
Chenodeoxycholic acid	The metabolism of Chenodeoxycholic acid can be decreased when combined with Lopinavir.	Approved
Chloramphenicol	The metabolism of Chloramphenicol can be increased when combined with Lopinavir.	Approved, Vet Approved
Chlordiazepoxide	The metabolism of Chlordiazepoxide can be decreased when combined with Lopinavir.	Approved, Illicit, Investigational
Chlormadinone	The serum concentration of Chlormadinone can be decreased when it is combined with Lopinavir.	Experimental
Chloroquine	Chloroquine may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational, Vet Approved
Chlorphenamine	The risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Lopinavir.	Approved
Chlorpromazine	Chlorpromazine may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational, Vet Approved
Chlorpropamide	The metabolism of Chlorpropamide can be increased when combined with Lopinavir.	Approved, Investigational
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Lopinavir.	Approved
Cholecalciferol	The metabolism of Cholecalciferol can be decreased when combined with Lopinavir.	Approved, Nutraceutical
Ciclesonide	The metabolism of Ciclesonide can be decreased when combined with Lopinavir.	Approved, Investigational
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lopinavir.	Experimental
Cilnidipine	The metabolism of Cilnidipine can be decreased when combined with Lopinavir.	Approved, Investigational
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Lopinavir.	Approved, Investigational
Cimetidine	The serum concentration of Cimetidine can be increased when it is combined with Lopinavir.	Approved, Investigational
Cinacalcet	The metabolism of Cinacalcet can be decreased when combined with Lopinavir.	Approved
Cinnarizine	The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Lopinavir.	Approved, Investigational
Ciprofloxacin	The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Lopinavir.	Approved, Investigational
Cisapride	The risk or severity of QTc prolongation can be increased when Cisapride is combined with Lopinavir.	Approved, Investigational, Withdrawn
Citalopram	The risk or severity of QTc prolongation can be increased when Citalopram is combined with Lopinavir.	Approved
Clarithromycin	Clarithromycin may increase the QTc-prolonging activities of Lopinavir.	Approved
Clemastine	The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Clemastine.	Approved, Investigational
Clevidipine	The metabolism of Clevidipine can be decreased when combined with Lopinavir.	Approved, Investigational
Clindamycin	The metabolism of Clindamycin can be decreased when combined with Lopinavir.	Approved, Vet Approved
Clobazam	The metabolism of Clobazam can be decreased when combined with Lopinavir.	Approved, Illicit
Clobetasol	The serum concentration of Clobetasol can be increased when it is combined with Lopinavir.	Approved, Investigational
Clobetasol propionate	The serum concentration of Clobetasol propionate can be increased when it is combined with Lopinavir.	Approved
Clobetasone	The serum concentration of Clobetasone can be increased when it is combined with Lopinavir.	Approved
Clocortolone	The serum concentration of Clocortolone can be increased when it is combined with Lopinavir.	Approved
Clofazimine	The metabolism of Clofazimine can be decreased when combined with Lopinavir.	Approved, Investigational
Clofibrate	The metabolism of Clofibrate can be decreased when combined with Lopinavir.	Approved, Investigational
clomethiazole	The metabolism of clomethiazole can be decreased when combined with Lopinavir.	Investigational
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Clonazepam	The metabolism of Clonazepam can be decreased when combined with Lopinavir.	Approved, Illicit
Clonidine	The metabolism of Clonidine can be decreased when combined with Lopinavir.	Approved
Clopidogrel	The metabolism of Clopidogrel can be decreased when combined with Lopinavir.	Approved
Clorazepate	The metabolism of Clorazepate can be decreased when combined with Lopinavir.	Approved, Illicit
Clotiazepam	The metabolism of Clotiazepam can be decreased when combined with Lopinavir.	Approved, Illicit
Clotrimazole	The metabolism of Lopinavir can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	Clozapine may increase the QTc-prolonging activities of Lopinavir.	Approved
Cobicistat	The metabolism of Lopinavir can be decreased when combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Lopinavir.	Approved, Investigational
Cocaine	The metabolism of Cocaine can be decreased when combined with Lopinavir.	Approved, Illicit
Codeine	The therapeutic efficacy of Codeine can be decreased when used in combination with Lopinavir.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Lopinavir.	Approved
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Lopinavir.	Approved, Investigational
Conjugated estrogens	The metabolism of Conjugated estrogens can be decreased when combined with Lopinavir.	Approved
Copanlisib	The metabolism of Copanlisib can be decreased when combined with Lopinavir.	Approved, Investigational
Cortexolone 17α-propionate	The serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Lopinavir.	Investigational
Corticosterone	The serum concentration of Corticosterone can be increased when it is combined with Lopinavir.	Experimental
Cortisone acetate	The metabolism of Cortisone acetate can be decreased when combined with Lopinavir.	Approved, Investigational
Crizotinib	The serum concentration of Crizotinib can be increased when it is combined with Lopinavir.	Approved
Curcumin	The metabolism of Lopinavir can be decreased when combined with Curcumin.	Approved, Investigational
Cyclandelate	The metabolism of Cyclandelate can be decreased when combined with Lopinavir.	Approved
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be decreased when combined with Lopinavir.	Approved
Cyclophosphamide	The risk or severity of adverse effects can be increased when Lopinavir is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The metabolism of Cyclosporine can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Cyproterone acetate	The serum concentration of Cyproterone acetate can be decreased when it is combined with Lopinavir.	Approved, Investigational
Cytarabine	The metabolism of Cytarabine can be decreased when combined with Lopinavir.	Approved, Investigational
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lopinavir.	Approved
Dabrafenib	The serum concentration of Lopinavir can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Daclatasvir	The serum concentration of Daclatasvir can be increased when it is combined with Lopinavir.	Approved, Investigational
Dantrolene	The metabolism of Dantrolene can be decreased when combined with Lopinavir.	Approved, Investigational
Dapagliflozin	The metabolism of Dapagliflozin can be decreased when combined with Lopinavir.	Approved
Dapoxetine	The serum concentration of Dapoxetine can be increased when it is combined with Lopinavir.	Investigational
Dapsone	The metabolism of Dapsone can be decreased when combined with Lopinavir.	Approved, Investigational
Darifenacin	The metabolism of Darifenacin can be decreased when combined with Lopinavir.	Approved, Investigational
Darodipine	The metabolism of Darodipine can be decreased when combined with Lopinavir.	Experimental
Darunavir	The serum concentration of Darunavir can be decreased when it is combined with Lopinavir.	Approved
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Lopinavir.	Approved
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Lopinavir.	Approved, Investigational
Daunorubicin	The metabolism of Daunorubicin can be decreased when combined with Lopinavir.	Approved
Debrisoquin	The metabolism of Debrisoquin can be decreased when combined with Lopinavir.	Approved, Investigational
Deferasirox	The serum concentration of Lopinavir can be decreased when it is combined with Deferasirox.	Approved, Investigational
Deflazacort	The metabolism of Deflazacort can be decreased when combined with Lopinavir.	Approved, Investigational
Degarelix	Degarelix may increase the QTc-prolonging activities of Lopinavir.	Approved
Delamanid	Lopinavir may increase the QTc-prolonging activities of Delamanid.	Approved, Investigational
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Lopinavir.	Approved
Deoxyspergualin	The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Lopinavir.	Investigational
Desflurane	Desflurane may increase the QTc-prolonging activities of Lopinavir.	Approved
Desipramine	The metabolism of Desipramine can be decreased when combined with Lopinavir.	Approved, Investigational
Desogestrel	The serum concentration of Desogestrel can be decreased when it is combined with Lopinavir.	Approved
Desonide	The serum concentration of Desonide can be increased when it is combined with Lopinavir.	Approved, Investigational
Desoximetasone	The serum concentration of Desoximetasone can be increased when it is combined with Lopinavir.	Approved
Desoxycorticosterone acetate	The serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Lopinavir.	Approved
Desoxycorticosterone Pivalate	The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Lopinavir.	Experimental, Vet Approved
Desvenlafaxine	The metabolism of Desvenlafaxine can be decreased when combined with Lopinavir.	Approved, Investigational
Deutetrabenazine	The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Lopinavir.	Approved, Investigational
Dexamethasone	The metabolism of Dexamethasone can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Lopinavir.	Vet Approved
Dexbrompheniramine	The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lopinavir.	Approved
Dexchlorpheniramine maleate	The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Lopinavir.	Approved
Dexfenfluramine	The metabolism of Dexfenfluramine can be decreased when combined with Lopinavir.	Approved, Illicit, Investigational, Withdrawn
Dexlansoprazole	The metabolism of Dexlansoprazole can be decreased when combined with Lopinavir.	Approved, Investigational
Dexniguldipine	The metabolism of Dexniguldipine can be decreased when combined with Lopinavir.	Experimental
Dextroamphetamine	The metabolism of Dextroamphetamine can be decreased when combined with Lopinavir.	Approved, Illicit
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Lopinavir.	Approved
Dextropropoxyphene	The metabolism of Dextropropoxyphene can be decreased when combined with Lopinavir.	Approved, Illicit, Investigational, Withdrawn
Dexverapamil	The metabolism of Dexverapamil can be decreased when combined with Lopinavir.	Experimental
Diazepam	The metabolism of Diazepam can be decreased when combined with Lopinavir.	Approved, Illicit, Investigational, Vet Approved
Dibenzepin	The serum concentration of Dibenzepin can be increased when it is combined with Lopinavir.	Experimental
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Lopinavir.	Approved, Vet Approved
Didanosine	The serum concentration of Didanosine can be decreased when it is combined with Lopinavir.	Approved
Dienogest	The serum concentration of Dienogest can be decreased when it is combined with Lopinavir.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Lopinavir.	Approved, Investigational
Diflorasone	The serum concentration of Diflorasone can be increased when it is combined with Lopinavir.	Approved
Difluocortolone	The serum concentration of Difluocortolone can be increased when it is combined with Lopinavir.	Approved, Investigational, Withdrawn
Difluprednate	The serum concentration of Difluprednate can be increased when it is combined with Lopinavir.	Approved
Digitoxin	The metabolism of Digitoxin can be decreased when combined with Lopinavir.	Approved, Investigational
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Lopinavir.	Approved
Dihydro-alpha-ergocryptine	The metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Lopinavir.	Approved
Dihydrocodeine	The metabolism of Dihydrocodeine can be decreased when combined with Lopinavir.	Approved, Illicit
Dihydroergocornine	The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lopinavir.	Approved
Dihydroergocristine	The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lopinavir.	Approved, Experimental
Dihydroergocryptine	The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Lopinavir.	Experimental
Dihydroergotamine	The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lopinavir.	Approved, Investigational
Diltiazem	The metabolism of Diltiazem can be decreased when combined with Lopinavir.	Approved, Investigational
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Lopinavir.	Approved
Dimetacrine	The serum concentration of Dimetacrine can be increased when it is combined with Lopinavir.	Approved, Withdrawn
Diphenhydramine	The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Lopinavir.	Approved, Investigational
Disopyramide	The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Lopinavir.	Approved
Disulfiram	The risk or severity of adverse effects can be increased when Lopinavir is combined with Disulfiram.	Approved
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Lopinavir.	Approved, Investigational
Dofetilide	The serum concentration of Dofetilide can be increased when it is combined with Lopinavir.	Approved, Investigational
Dolasetron	Dolasetron may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Lopinavir.	Approved, Investigational, Vet Approved
Donepezil	The metabolism of Donepezil can be decreased when combined with Lopinavir.	Approved
Dopamine	The metabolism of Dopamine can be decreased when combined with Lopinavir.	Approved
Dorzolamide	The metabolism of Dorzolamide can be decreased when combined with Lopinavir.	Approved
Dosulepin	The serum concentration of Dosulepin can be increased when it is combined with Lopinavir.	Approved
Dotarizine	The metabolism of Dotarizine can be decreased when combined with Lopinavir.	Investigational
Doxepin	The metabolism of Doxepin can be decreased when combined with Lopinavir.	Approved, Investigational
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Lopinavir.	Approved, Investigational
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Lopinavir.	Approved, Investigational
Doxycycline	The metabolism of Lopinavir can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Lopinavir.	Approved, Vet Approved
Dronabinol	The serum concentration of Dronabinol can be increased when it is combined with Lopinavir.	Approved, Illicit
Dronedarone	The serum concentration of Dronedarone can be increased when it is combined with Lopinavir.	Approved
Droperidol	Droperidol may increase the QTc-prolonging activities of Lopinavir.	Approved, Vet Approved
Drospirenone	The serum concentration of Drospirenone can be decreased when it is combined with Lopinavir.	Approved
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lopinavir.	Approved, Investigational
Duloxetine	The serum concentration of Duloxetine can be increased when it is combined with Lopinavir.	Approved
Dutasteride	The serum concentration of Dutasteride can be increased when it is combined with Lopinavir.	Approved, Investigational
Dyphylline	The serum concentration of Dyphylline can be decreased when it is combined with Lopinavir.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Lopinavir.	Approved
Efavirenz	The serum concentration of Lopinavir can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efonidipine	The metabolism of Efonidipine can be decreased when combined with Lopinavir.	Approved, Investigational
Elbasvir	The metabolism of Elbasvir can be decreased when combined with Lopinavir.	Approved
Eletriptan	The metabolism of Eletriptan can be decreased when combined with Lopinavir.	Approved, Investigational
Eliglustat	The serum concentration of Eliglustat can be increased when it is combined with Lopinavir.	Approved
Eluxadoline	The serum concentration of Eluxadoline can be increased when it is combined with Lopinavir.	Approved, Investigational
Elvitegravir	The serum concentration of Elvitegravir can be increased when it is combined with Lopinavir.	Approved
Emopamil	The metabolism of Emopamil can be decreased when combined with Lopinavir.	Experimental
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lopinavir.	Approved
Enalapril	The metabolism of Enalapril can be decreased when combined with Lopinavir.	Approved, Vet Approved
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Lopinavir.	Approved, Investigational
Encainide	The metabolism of Encainide can be decreased when combined with Lopinavir.	Approved, Investigational, Withdrawn
Enclomiphene	The metabolism of Enclomiphene can be decreased when combined with Lopinavir.	Investigational
Enfuvirtide	The serum concentration of Enfuvirtide can be increased when it is combined with Lopinavir.	Approved, Investigational
Englitazone	The therapeutic efficacy of Englitazone can be decreased when used in combination with Lopinavir.	Experimental
Enzalutamide	The serum concentration of Lopinavir can be decreased when it is combined with Enzalutamide.	Approved
Eperisone	The metabolism of Eperisone can be decreased when combined with Lopinavir.	Approved, Investigational
Epinastine	The metabolism of Epinastine can be decreased when combined with Lopinavir.	Approved, Investigational
Eplerenone	The serum concentration of Eplerenone can be increased when it is combined with Lopinavir.	Approved
Equilenin	The serum concentration of Equilenin can be increased when it is combined with Lopinavir.	Experimental
Equilin	The serum concentration of Equilin can be increased when it is combined with Lopinavir.	Approved
Ergocalciferol	The metabolism of Ergocalciferol can be decreased when combined with Lopinavir.	Approved, Nutraceutical
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be increased when it is combined with Lopinavir.	Approved
Ergonovine	The risk or severity of adverse effects can be increased when Ergonovine is combined with Lopinavir.	Approved
Ergotamine	The risk or severity of adverse effects can be increased when Ergotamine is combined with Lopinavir.	Approved
Eribulin	Eribulin may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Lopinavir.	Approved, Investigational
Erythromycin	Erythromycin may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational, Vet Approved
Escitalopram	The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Lopinavir.	Approved, Investigational
Esmirtazapine	The metabolism of Esmirtazapine can be decreased when combined with Lopinavir.	Investigational
Esomeprazole	The metabolism of Esomeprazole can be decreased when combined with Lopinavir.	Approved, Investigational
Estazolam	The serum concentration of Estazolam can be increased when it is combined with Lopinavir.	Approved, Illicit
Estradiol	The metabolism of Estradiol can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Estradiol acetate	The metabolism of Estradiol acetate can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Estradiol benzoate	The metabolism of Estradiol benzoate can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Estradiol cypionate	The metabolism of Estradiol cypionate can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Estradiol dienanthate	The metabolism of Estradiol dienanthate can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Estradiol valerate	The metabolism of Estradiol valerate can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Estramustine	The metabolism of Estramustine can be decreased when combined with Lopinavir.	Approved, Investigational
Estrogens, esterified	The metabolism of Estrogens, esterified can be decreased when combined with Lopinavir.	Approved
Estrone	The metabolism of Estrone can be decreased when combined with Lopinavir.	Approved
Estrone sulfate	The metabolism of Estrone sulfate can be decreased when combined with Lopinavir.	Approved
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Lopinavir.	Approved, Investigational
Ethanol	The metabolism of Ethanol can be decreased when combined with Lopinavir.	Approved
Ethinyl Estradiol	The metabolism of Ethinyl Estradiol can be decreased when combined with Lopinavir.	Approved
Ethosuximide	The metabolism of Ethosuximide can be decreased when combined with Lopinavir.	Approved
Ethylmorphine	The metabolism of Ethylmorphine can be decreased when combined with Lopinavir.	Approved, Illicit
Ethynodiol diacetate	The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Lopinavir.	Approved
Etizolam	The serum concentration of Etizolam can be increased when it is combined with Lopinavir.	Approved
Etonogestrel	The serum concentration of Etonogestrel can be decreased when it is combined with Lopinavir.	Approved, Investigational
Etoposide	The metabolism of Etoposide can be decreased when combined with Lopinavir.	Approved
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Lopinavir.	Approved, Investigational
Etravirine	The serum concentration of Etravirine can be decreased when it is combined with Lopinavir.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Lopinavir.	Approved
Exemestane	The metabolism of Exemestane can be decreased when combined with Lopinavir.	Approved, Investigational
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Lopinavir.	Approved, Investigational
Ezogabine	Ezogabine may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Famciclovir	The metabolism of Famciclovir can be decreased when combined with Lopinavir.	Approved, Investigational
Famotidine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lopinavir.	Approved
Felbamate	The metabolism of Felbamate can be decreased when combined with Lopinavir.	Approved
Felodipine	The metabolism of Felodipine can be decreased when combined with Lopinavir.	Approved, Investigational
Fendiline	The metabolism of Fendiline can be decreased when combined with Lopinavir.	Withdrawn
Fenofibrate	The metabolism of Fenofibrate can be decreased when combined with Lopinavir.	Approved
Fentanyl	The serum concentration of Fentanyl can be increased when it is combined with Lopinavir.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lopinavir.	Approved
Finasteride	The metabolism of Finasteride can be decreased when combined with Lopinavir.	Approved
Fingolimod	The metabolism of Fingolimod can be decreased when combined with Lopinavir.	Approved, Investigational
Fish oil	The metabolism of Fish oil can be decreased when combined with Lopinavir.	Approved, Nutraceutical
Flecainide	Flecainide may increase the QTc-prolonging activities of Lopinavir.	Approved, Withdrawn
Flibanserin	The serum concentration of Flibanserin can be increased when it is combined with Lopinavir.	Approved, Investigational
Fluasterone	The serum concentration of Fluasterone can be increased when it is combined with Lopinavir.	Investigational
Fluconazole	Fluconazole may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Fludrocortisone	The serum concentration of Fludrocortisone can be increased when it is combined with Lopinavir.	Approved, Investigational
Flumethasone	The serum concentration of Flumethasone can be increased when it is combined with Lopinavir.	Approved, Vet Approved
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Lopinavir.	Approved
Flunisolide	The metabolism of Flunisolide can be decreased when combined with Lopinavir.	Approved, Investigational
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Lopinavir.	Approved, Illicit
Fluocinolone Acetonide	The serum concentration of Fluocinolone Acetonide can be increased when it is combined with Lopinavir.	Approved, Investigational, Vet Approved
Fluocinonide	The serum concentration of Fluocinonide can be increased when it is combined with Lopinavir.	Approved, Investigational
Fluocortolone	The serum concentration of Fluocortolone can be increased when it is combined with Lopinavir.	Approved, Withdrawn
Fluorometholone	The metabolism of Fluorometholone can be decreased when combined with Lopinavir.	Approved, Investigational
Fluoxetine	The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Lopinavir.	Approved, Vet Approved
Flupentixol	The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Lopinavir.	Approved, Investigational, Withdrawn
Fluphenazine	The metabolism of Fluphenazine can be decreased when combined with Lopinavir.	Approved
Fluprednidene	The serum concentration of Fluprednidene can be increased when it is combined with Lopinavir.	Approved, Withdrawn
Fluprednisolone	The serum concentration of Fluprednisolone can be increased when it is combined with Lopinavir.	Approved
Flurandrenolide	The serum concentration of Flurandrenolide can be increased when it is combined with Lopinavir.	Approved
Flurazepam	The metabolism of Flurazepam can be decreased when combined with Lopinavir.	Approved, Illicit, Investigational
Fluspirilene	The metabolism of Fluspirilene can be decreased when combined with Lopinavir.	Approved, Investigational
Flutamide	The metabolism of Flutamide can be decreased when combined with Lopinavir.	Approved, Investigational
Fluticasone	The serum concentration of Fluticasone can be increased when it is combined with Lopinavir.	Approved, Experimental, Investigational
Fluticasone furoate	The metabolism of Fluticasone furoate can be decreased when combined with Lopinavir.	Approved
Fluticasone propionate	The serum concentration of Fluticasone propionate can be increased when it is combined with Lopinavir.	Approved
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Lopinavir.	Approved
Fluvoxamine	The metabolism of Lopinavir can be decreased when combined with Fluvoxamine.	Approved, Investigational
Formestane	The serum concentration of Formestane can be increased when it is combined with Lopinavir.	Approved, Investigational, Withdrawn
Formoterol	The metabolism of Formoterol can be decreased when combined with Lopinavir.	Approved, Investigational
Fosamprenavir	The serum concentration of Lopinavir can be decreased when it is combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Lopinavir can be increased when it is combined with Fosaprepitant.	Approved
Foscarnet	Foscarnet may increase the QTc-prolonging activities of Lopinavir.	Approved
Fosnetupitant	The metabolism of Fosnetupitant can be decreased when combined with Lopinavir.	Approved
Fosphenytoin	The serum concentration of Lopinavir can be decreased when it is combined with Fosphenytoin.	Approved, Investigational
Fostamatinib	The metabolism of Fostamatinib can be decreased when combined with Lopinavir.	Approved, Investigational
Fulvestrant	The metabolism of Fulvestrant can be decreased when combined with Lopinavir.	Approved, Investigational
Fusidic Acid	The serum concentration of Lopinavir can be increased when it is combined with Fusidic Acid.	Approved, Investigational
Gabapentin	The metabolism of Gabapentin can be decreased when combined with Lopinavir.	Approved, Investigational
Gadobenic acid	Gadobenic acid may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Galantamine	The metabolism of Galantamine can be decreased when combined with Lopinavir.	Approved
Gallopamil	The metabolism of Gallopamil can be decreased when combined with Lopinavir.	Investigational
Garlic	The serum concentration of Lopinavir can be decreased when it is combined with Garlic.	Approved, Nutraceutical
Gefitinib	The metabolism of Gefitinib can be decreased when combined with Lopinavir.	Approved, Investigational
Gemfibrozil	The metabolism of Gemfibrozil can be decreased when combined with Lopinavir.	Approved
Gemifloxacin	Gemifloxacin may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Gestodene	The serum concentration of Gestodene can be decreased when it is combined with Lopinavir.	Approved, Investigational
Gestrinone	The serum concentration of Gestrinone can be decreased when it is combined with Lopinavir.	Approved
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Lopinavir.	Investigational, Withdrawn
Gliclazide	The metabolism of Gliclazide can be increased when combined with Lopinavir.	Approved
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lopinavir.	Approved
Glipizide	The metabolism of Glipizide can be decreased when combined with Lopinavir.	Approved, Investigational
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Lopinavir.	Approved, Investigational
Glucosamine	The metabolism of Glucosamine can be increased when combined with Lopinavir.	Approved, Investigational
Glyburide	The metabolism of Glyburide can be decreased when combined with Lopinavir.	Approved
Goserelin	Goserelin may increase the QTc-prolonging activities of Lopinavir.	Approved
Granisetron	Granisetron may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Grazoprevir	The metabolism of Grazoprevir can be decreased when combined with Lopinavir.	Approved
Grepafloxacin	The metabolism of Grepafloxacin can be decreased when combined with Lopinavir.	Approved, Investigational, Withdrawn
Guanfacine	The serum concentration of Guanfacine can be increased when it is combined with Lopinavir.	Approved, Investigational
Gusperimus	The therapeutic efficacy of Gusperimus can be decreased when used in combination with Lopinavir.	Investigational
Halcinonide	The serum concentration of Halcinonide can be increased when it is combined with Lopinavir.	Approved, Investigational, Withdrawn
Halofantrine	The serum concentration of Halofantrine can be increased when it is combined with Lopinavir.	Approved
Haloperidol	Haloperidol may increase the QTc-prolonging activities of Lopinavir.	Approved
Halothane	The metabolism of Halothane can be decreased when combined with Lopinavir.	Approved, Vet Approved
HE3286	The serum concentration of HE3286 can be increased when it is combined with Lopinavir.	Investigational
Hexobarbital	The metabolism of Hexobarbital can be decreased when combined with Lopinavir.	Approved
Histamine	The metabolism of Histamine can be decreased when combined with Lopinavir.	Approved, Investigational
Histrelin	Histrelin may increase the QTc-prolonging activities of Lopinavir.	Approved
Hydrocodone	The metabolism of Hydrocodone can be decreased when combined with Lopinavir.	Approved, Illicit
Hydrocortisone	The metabolism of Hydrocortisone can be decreased when combined with Lopinavir.	Approved, Vet Approved
Hydrocortisone acetate	The metabolism of Hydrocortisone acetate can be decreased when combined with Lopinavir.	Approved, Vet Approved
Hydrocortisone butyrate	The metabolism of Hydrocortisone butyrate can be decreased when combined with Lopinavir.	Approved, Vet Approved
Hydromorphone	The metabolism of Hydromorphone can be decreased when combined with Lopinavir.	Approved, Illicit
Hydroxyprogesterone caproate	The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Lopinavir.	Approved, Investigational
Hydroxyzine	The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Lopinavir.	Approved
Ibandronate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lopinavir.	Approved, Investigational
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Lopinavir.	Approved
Ibutilide	The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Lopinavir.	Approved
Icotinib	The metabolism of Icotinib can be decreased when combined with Lopinavir.	Approved, Investigational
Idarubicin	The metabolism of Idarubicin can be decreased when combined with Lopinavir.	Approved
Idelalisib	The serum concentration of Idelalisib can be increased when it is combined with Lopinavir.	Approved
Ifosfamide	The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Lopinavir resulting in a loss in efficacy.	Approved
Iloperidone	The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Lopinavir.	Approved
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Lopinavir.	Approved
Imidafenacin	The serum concentration of Imidafenacin can be increased when it is combined with Lopinavir.	Approved, Investigational
Imipramine	The metabolism of Imipramine can be decreased when combined with Lopinavir.	Approved
Imiquimod	The metabolism of Imiquimod can be decreased when combined with Lopinavir.	Approved, Investigational
Indacaterol	The metabolism of Indacaterol can be decreased when combined with Lopinavir.	Approved
Indapamide	The metabolism of Indapamide can be decreased when combined with Lopinavir.	Approved
Indinavir	The metabolism of Lopinavir can be decreased when combined with Indinavir.	Approved
Indomethacin	The metabolism of Indomethacin can be increased when combined with Lopinavir.	Approved, Investigational
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lopinavir.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Lopinavir.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lopinavir.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Lopinavir.	Approved
Insulin Human	The therapeutic efficacy of Insulin Human can be decreased when used in combination with Lopinavir.	Approved, Investigational
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lopinavir.	Approved
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lopinavir.	Approved
Ipecac	The metabolism of Ipecac can be decreased when combined with Lopinavir.	Approved, Withdrawn
Ipratropium	The metabolism of Ipratropium can be decreased when combined with Lopinavir.	Approved
Iprindole	The serum concentration of Iprindole can be increased when it is combined with Lopinavir.	Experimental
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Lopinavir.	Approved, Investigational
Isavuconazole	The serum concentration of Isavuconazole can be increased when it is combined with Lopinavir.	Approved, Investigational
Isavuconazole	The serum concentration of Lopinavir can be decreased when it is combined with Isavuconazole.	Approved, Investigational
Isavuconazonium	The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Lopinavir.	Approved, Investigational
Isoflurane	Isoflurane may increase the QTc-prolonging activities of Lopinavir.	Approved, Vet Approved
Isosorbide Dinitrate	The metabolism of Isosorbide Dinitrate can be decreased when combined with Lopinavir.	Approved, Investigational
Isosorbide Mononitrate	The metabolism of Isosorbide Mononitrate can be decreased when combined with Lopinavir.	Approved
Isradipine	The risk or severity of QTc prolongation can be increased when Isradipine is combined with Lopinavir.	Approved, Investigational
Istaroxime	The serum concentration of Istaroxime can be increased when it is combined with Lopinavir.	Investigational
Itraconazole	The serum concentration of Itraconazole can be increased when it is combined with Lopinavir.	Approved, Investigational
Ivabradine	The serum concentration of Ivabradine can be increased when it is combined with Lopinavir.	Approved
Ivacaftor	The serum concentration of Ivacaftor can be increased when it is combined with Lopinavir.	Approved
Ivermectin	The metabolism of Ivermectin can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Ixabepilone	The serum concentration of Ixabepilone can be increased when it is combined with Lopinavir.	Approved, Investigational
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Lopinavir.	Approved, Investigational
Ketamine	The metabolism of Ketamine can be decreased when combined with Lopinavir.	Approved, Vet Approved
Ketazolam	The metabolism of Ketazolam can be decreased when combined with Lopinavir.	Approved
Ketobemidone	The metabolism of Ketobemidone can be decreased when combined with Lopinavir.	Approved, Investigational
Ketoconazole	The serum concentration of Lopinavir can be increased when it is combined with Ketoconazole.	Approved, Investigational
Labetalol	The metabolism of Labetalol can be decreased when combined with Lopinavir.	Approved
Lacidipine	The serum concentration of Lacidipine can be increased when it is combined with Lopinavir.	Approved, Investigational
Lacosamide	The serum concentration of Lacosamide can be increased when it is combined with Lopinavir.	Approved
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Lopinavir.	Approved, Investigational
Lamotrigine	The metabolism of Lamotrigine can be decreased when combined with Lopinavir.	Approved, Investigational
Lansoprazole	The metabolism of Lansoprazole can be decreased when combined with Lopinavir.	Approved, Investigational
Lapatinib	The serum concentration of Lapatinib can be increased when it is combined with Lopinavir.	Approved, Investigational
Laquinimod	The metabolism of Laquinimod can be decreased when combined with Lopinavir.	Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Lopinavir.	Approved
Lenvatinib	Lenvatinib may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Lercanidipine	The serum concentration of Lercanidipine can be increased when it is combined with Lopinavir.	Approved, Investigational
Letermovir	The metabolism of Letermovir can be decreased when combined with Lopinavir.	Approved, Investigational
Letrozole	The metabolism of Letrozole can be decreased when combined with Lopinavir.	Approved, Investigational
Leuprolide	Leuprolide may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Levetiracetam	The metabolism of Levetiracetam can be decreased when combined with Lopinavir.	Approved, Investigational
Levobupivacaine	The serum concentration of Levobupivacaine can be increased when it is combined with Lopinavir.	Approved, Investigational
Levocetirizine	The metabolism of Levocetirizine can be decreased when combined with Lopinavir.	Approved
Levofloxacin	Levofloxacin may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Levomethadyl Acetate	The metabolism of Levomethadyl Acetate can be decreased when combined with Lopinavir.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Lopinavir.	Approved, Investigational
Levonorgestrel	The serum concentration of Levonorgestrel can be decreased when it is combined with Lopinavir.	Approved, Investigational
Levothyroxine	The metabolism of Levothyroxine can be decreased when combined with Lopinavir.	Approved
Lidocaine	The metabolism of Lidocaine can be decreased when combined with Lopinavir.	Approved, Vet Approved
Lidoflazine	The metabolism of Lidoflazine can be decreased when combined with Lopinavir.	Experimental
Linagliptin	The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lopinavir.	Approved
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Lopinavir.	Approved
Lisuride	The risk or severity of adverse effects can be increased when Lisuride is combined with Lopinavir.	Approved, Investigational
Lithium cation	Lithium may increase the QTc-prolonging activities of Lopinavir.	Experimental
Lofepramine	The serum concentration of Lofepramine can be increased when it is combined with Lopinavir.	Experimental
Lofexidine	The metabolism of Lofexidine can be decreased when combined with Lopinavir.	Approved, Investigational
Lomerizine	The metabolism of Lomerizine can be decreased when combined with Lopinavir.	Experimental
Lomitapide	The serum concentration of Lomitapide can be increased when it is combined with Lopinavir.	Approved, Investigational
Lomustine	The metabolism of Lomustine can be decreased when combined with Lopinavir.	Approved, Investigational
Loperamide	The metabolism of Loperamide can be decreased when combined with Lopinavir.	Approved
Loratadine	The risk or severity of QTc prolongation can be increased when Loratadine is combined with Lopinavir.	Approved, Investigational
Lorcaserin	The metabolism of Lorcaserin can be decreased when combined with Lopinavir.	Approved
Lorpiprazole	The serum concentration of Lopinavir can be increased when it is combined with Lorpiprazole.	Approved
Losartan	The metabolism of Losartan can be decreased when combined with Lopinavir.	Approved
Loteprednol	The serum concentration of Loteprednol can be increased when it is combined with Lopinavir.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Lopinavir.	Approved, Investigational
Luliconazole	The serum concentration of Lopinavir can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Lumacaftor can be increased when it is combined with Lopinavir.	Approved
Lumefantrine	The serum concentration of Lumefantrine can be increased when it is combined with Lopinavir.	Approved
Lumiracoxib	The metabolism of Lumiracoxib can be increased when combined with Lopinavir.	Approved, Investigational
Lurasidone	The serum concentration of Lurasidone can be increased when it is combined with Lopinavir.	Approved, Investigational
Lynestrenol	The serum concentration of Lynestrenol can be decreased when it is combined with Lopinavir.	Approved, Investigational
Lysergic Acid Diethylamide	The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Lopinavir.	Illicit, Investigational, Withdrawn
Macimorelin	The metabolism of Macimorelin can be decreased when combined with Lopinavir.	Approved, Investigational
Macitentan	The serum concentration of Macitentan can be increased when it is combined with Lopinavir.	Approved
Magnesium sulfate	The metabolism of Magnesium sulfate can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Manidipine	The metabolism of Manidipine can be decreased when combined with Lopinavir.	Approved, Investigational
Maprotiline	The metabolism of Maprotiline can be decreased when combined with Lopinavir.	Approved, Investigational
Maraviroc	The serum concentration of Maraviroc can be increased when it is combined with Lopinavir.	Approved, Investigational
ME-609	The serum concentration of ME-609 can be increased when it is combined with Lopinavir.	Investigational
Mebendazole	The metabolism of Mebendazole can be decreased when combined with Lopinavir.	Approved, Vet Approved
Medical Cannabis	The metabolism of Medical Cannabis can be decreased when combined with Lopinavir.	Experimental, Investigational
Medroxyprogesterone acetate	The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Lopinavir.	Approved, Investigational
Medrysone	The serum concentration of Medrysone can be increased when it is combined with Lopinavir.	Approved
Mefloquine	The metabolism of Mefloquine can be decreased when combined with Lopinavir.	Approved, Investigational
Megestrol acetate	The serum concentration of Megestrol acetate can be decreased when it is combined with Lopinavir.	Approved, Investigational, Vet Approved
Melatonin	The metabolism of Melatonin can be increased when combined with Lopinavir.	Approved, Nutraceutical, Vet Approved
Melengestrol	The serum concentration of Melengestrol can be increased when it is combined with Lopinavir.	Vet Approved
Melitracen	The serum concentration of Melitracen can be increased when it is combined with Lopinavir.	Experimental, Investigational
Meloxicam	The metabolism of Meloxicam can be decreased when combined with Lopinavir.	Approved, Vet Approved
Menthol	The metabolism of Menthol can be decreased when combined with Lopinavir.	Approved
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Lopinavir.	Investigational, Withdrawn
Meprobamate	The metabolism of Meprobamate can be increased when combined with Lopinavir.	Approved, Illicit
Mepyramine	The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Lopinavir.	Approved, Vet Approved
Mequitazine	The serum concentration of Mequitazine can be increased when it is combined with Lopinavir.	Approved
Mesoridazine	The metabolism of Mesoridazine can be decreased when combined with Lopinavir.	Approved, Investigational
Mestranol	The serum concentration of Mestranol can be decreased when it is combined with Lopinavir.	Approved
Metergoline	The risk or severity of adverse effects can be increased when Metergoline is combined with Lopinavir.	Experimental
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir.	Approved
Methadone	Methadone may increase the QTc-prolonging activities of Lopinavir.	Approved
Methamphetamine	The metabolism of Methamphetamine can be decreased when combined with Lopinavir.	Approved, Illicit
Methaqualone	The metabolism of Methaqualone can be decreased when combined with Lopinavir.	Illicit, Withdrawn
Methotrimeprazine	The metabolism of Methotrimeprazine can be decreased when combined with Lopinavir.	Approved, Investigational
Methoxsalen	The metabolism of Methoxsalen can be decreased when combined with Lopinavir.	Approved
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Methylergometrine	The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lopinavir.	Approved
Methylphenobarbital	The metabolism of Methylphenobarbital can be increased when combined with Lopinavir.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Lopinavir.	Approved, Vet Approved
Methyltestosterone	The metabolism of Methyltestosterone can be decreased when combined with Lopinavir.	Approved
Methyprylon	The metabolism of Methyprylon can be decreased when combined with Lopinavir.	Approved, Illicit, Withdrawn
Methysergide	The risk or severity of adverse effects can be increased when Methysergide is combined with Lopinavir.	Approved
Metoclopramide	The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lopinavir.	Approved, Investigational
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Lopinavir.	Approved, Investigational
Metronidazole	The risk or severity of adverse effects can be increased when Metronidazole is combined with Lopinavir.	Approved
Mevastatin	The serum concentration of Mevastatin can be increased when it is combined with Lopinavir.	Experimental
Mexiletine	The metabolism of Mexiletine can be decreased when combined with Lopinavir.	Approved, Investigational
Mianserin	The metabolism of Mianserin can be decreased when combined with Lopinavir.	Approved, Investigational
Mibefradil	The metabolism of Mibefradil can be decreased when combined with Lopinavir.	Investigational, Withdrawn
Miconazole	The metabolism of Miconazole can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Lopinavir.	Approved, Illicit
Midecamycin	The metabolism of Midecamycin can be decreased when combined with Lopinavir.	Approved
Midostaurin	The metabolism of Midostaurin can be decreased when combined with Lopinavir.	Approved, Investigational
Mifepristone	Lopinavir may increase the QTc-prolonging activities of Mifepristone.	Approved, Investigational
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Lopinavir.	Approved
Miglustat	The therapeutic efficacy of Miglustat can be decreased when used in combination with Lopinavir.	Approved
Minaprine	The metabolism of Minaprine can be decreased when combined with Lopinavir.	Approved
Mirabegron	The metabolism of Mirabegron can be decreased when combined with Lopinavir.	Approved
Mirtazapine	The metabolism of Mirtazapine can be decreased when combined with Lopinavir.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Lopinavir.	Approved, Investigational
Mitotane	The serum concentration of Lopinavir can be decreased when it is combined with Mitotane.	Approved
Moclobemide	The metabolism of Moclobemide can be decreased when combined with Lopinavir.	Approved, Investigational
Modafinil	The metabolism of Modafinil can be decreased when combined with Lopinavir.	Approved, Investigational
Moexipril	Moexipril may increase the QTc-prolonging activities of Lopinavir.	Approved
Mometasone	The serum concentration of Mometasone can be increased when it is combined with Lopinavir.	Approved, Vet Approved
Montelukast	The metabolism of Montelukast can be decreased when combined with Lopinavir.	Approved
Morphine	The metabolism of Morphine can be decreased when combined with Lopinavir.	Approved, Investigational
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lopinavir.	Approved, Investigational
Mycophenolate mofetil	The metabolism of Mycophenolate mofetil can be decreased when combined with Lopinavir.	Approved, Investigational
Nabiximols	The metabolism of Nabiximols can be decreased when combined with Lopinavir.	Approved, Investigational
Naftopidil	The metabolism of Naftopidil can be decreased when combined with Lopinavir.	Investigational
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Lopinavir.	Approved
Naloxone	The metabolism of Naloxone can be decreased when combined with Lopinavir.	Approved, Vet Approved
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Lopinavir.	Approved, Investigational
NCX 1022	The serum concentration of NCX 1022 can be increased when it is combined with Lopinavir.	Investigational
Nebivolol	The serum concentration of Nebivolol can be increased when it is combined with Lopinavir.	Approved, Investigational
Nefazodone	The serum concentration of Nefazodone can be increased when it is combined with Lopinavir.	Approved, Withdrawn
Nelfinavir	The serum concentration of Lopinavir can be decreased when it is combined with Nelfinavir.	Approved
Neratinib	The metabolism of Neratinib can be decreased when combined with Lopinavir.	Approved, Investigational
Netupitant	The serum concentration of Lopinavir can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The serum concentration of Lopinavir can be decreased when it is combined with Nevirapine.	Approved
Nicardipine	The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Lopinavir.	Approved, Investigational
Nicergoline	The risk or severity of adverse effects can be increased when Nicergoline is combined with Lopinavir.	Approved, Investigational
Nicotine	The metabolism of Nicotine can be decreased when combined with Lopinavir.	Approved
Nifedipine	The metabolism of Nifedipine can be decreased when combined with Lopinavir.	Approved
Niguldipine	The metabolism of Niguldipine can be decreased when combined with Lopinavir.	Experimental
Nilotinib	The serum concentration of Nilotinib can be increased when it is combined with Lopinavir.	Approved, Investigational
Niludipine	The metabolism of Niludipine can be decreased when combined with Lopinavir.	Experimental
Nilutamide	The metabolism of Nilutamide can be increased when combined with Lopinavir.	Approved, Investigational
Nilvadipine	The metabolism of Nilvadipine can be decreased when combined with Lopinavir.	Approved, Investigational
Nimesulide	The metabolism of Nimesulide can be decreased when combined with Lopinavir.	Approved, Investigational, Withdrawn
Nimodipine	The serum concentration of Nimodipine can be increased when it is combined with Lopinavir.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Lopinavir.	Approved
Nisoldipine	The serum concentration of Nisoldipine can be increased when it is combined with Lopinavir.	Approved
Nitrazepam	The metabolism of Nitrazepam can be decreased when combined with Lopinavir.	Approved
Nitrendipine	The metabolism of Nitrendipine can be decreased when combined with Lopinavir.	Approved, Investigational
Nitrofural	The metabolism of Nitrofural can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Nomegestrol acetate	The serum concentration of Nomegestrol acetate can be decreased when it is combined with Lopinavir.	Approved, Investigational
Norelgestromin	The serum concentration of Norelgestromin can be decreased when it is combined with Lopinavir.	Approved, Investigational
Norethisterone	The serum concentration of Norethisterone can be decreased when it is combined with Lopinavir.	Approved
Norethynodrel	The serum concentration of Norethynodrel can be decreased when it is combined with Lopinavir.	Approved
Norfloxacin	Norfloxacin may increase the QTc-prolonging activities of Lopinavir.	Approved
Norgestimate	The serum concentration of Norgestimate can be decreased when it is combined with Lopinavir.	Approved, Investigational
Norgestrel	The serum concentration of Norgestrel can be decreased when it is combined with Lopinavir.	Approved
Norgestrienone	The serum concentration of Norgestrienone can be decreased when it is combined with Lopinavir.	Experimental
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Lopinavir.	Approved
Nylidrin	The metabolism of Nylidrin can be decreased when combined with Lopinavir.	Approved
Octreotide	Octreotide may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Odanacatib	The metabolism of Odanacatib can be decreased when combined with Lopinavir.	Investigational
Ofloxacin	Ofloxacin may increase the QTc-prolonging activities of Lopinavir.	Approved
Olanzapine	The metabolism of Olanzapine can be decreased when combined with Lopinavir.	Approved, Investigational
Olaparib	The serum concentration of Olaparib can be increased when it is combined with Lopinavir.	Approved
Oleoyl-estrone	The serum concentration of Oleoyl-estrone can be increased when it is combined with Lopinavir.	Investigational
Olodaterol	Olodaterol may increase the QTc-prolonging activities of Lopinavir.	Approved
Olopatadine	The metabolism of Olopatadine can be decreased when combined with Lopinavir.	Approved
Omeprazole	The metabolism of Omeprazole can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Ondansetron	The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Lopinavir.	Approved
Opipramol	The serum concentration of Opipramol can be increased when it is combined with Lopinavir.	Investigational
Opium	The metabolism of Opium can be decreased when combined with Lopinavir.	Approved, Illicit
Orphenadrine	The metabolism of Orphenadrine can be decreased when combined with Lopinavir.	Approved
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Lopinavir.	Approved
Ospemifene	The serum concentration of Ospemifene can be increased when it is combined with Lopinavir.	Approved, Investigational
Otilonium	The metabolism of Otilonium can be decreased when combined with Lopinavir.	Experimental, Investigational
Oxazepam	The metabolism of Oxazepam can be decreased when combined with Lopinavir.	Approved
Oxiconazole	The metabolism of Oxiconazole can be increased when combined with Lopinavir.	Approved
Oxybutynin	The serum concentration of Oxybutynin can be increased when it is combined with Lopinavir.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Lopinavir is combined with Oxycodone.	Approved, Illicit, Investigational
Oxymorphone	The metabolism of Oxymorphone can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Oxytocin	Oxytocin may increase the QTc-prolonging activities of Lopinavir.	Approved, Vet Approved
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Lopinavir.	Approved, Vet Approved
Palbociclib	The serum concentration of Palbociclib can be increased when it is combined with Lopinavir.	Approved, Investigational
Paliperidone	The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Lopinavir.	Approved
Palonosetron	The metabolism of Palonosetron can be decreased when combined with Lopinavir.	Approved, Investigational
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Lopinavir.	Approved, Investigational
Pantoprazole	The metabolism of Pantoprazole can be decreased when combined with Lopinavir.	Approved
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Lopinavir.	Approved
Paramethasone	The metabolism of Paramethasone can be decreased when combined with Lopinavir.	Approved
Parecoxib	The serum concentration of Parecoxib can be increased when it is combined with Lopinavir.	Approved
Paricalcitol	The serum concentration of Paricalcitol can be increased when it is combined with Lopinavir.	Approved, Investigational
Paritaprevir	The metabolism of Paritaprevir can be decreased when combined with Lopinavir.	Approved, Investigational
Paroxetine	The risk or severity of QTc prolongation can be increased when Paroxetine is combined with Lopinavir.	Approved, Investigational
Pasireotide	Pasireotide may increase the QTc-prolonging activities of Lopinavir.	Approved
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Lopinavir.	Approved
Penfluridol	The metabolism of Penfluridol can be decreased when combined with Lopinavir.	Experimental
Pentamidine	Pentamidine may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Pentobarbital	The serum concentration of Pentobarbital can be increased when it is combined with Lopinavir.	Approved, Investigational, Vet Approved
Perampanel	The metabolism of Perampanel can be decreased when combined with Lopinavir.	Approved
Perflutren	Perflutren may increase the QTc-prolonging activities of Lopinavir.	Approved
Pergolide	The risk or severity of adverse effects can be increased when Pergolide is combined with Lopinavir.	Approved, Investigational, Vet Approved, Withdrawn
Perhexiline	The metabolism of Perhexiline can be decreased when combined with Lopinavir.	Approved, Investigational
Permethrin	The metabolism of Permethrin can be decreased when combined with Lopinavir.	Approved, Investigational
Perospirone	The metabolism of Perospirone can be decreased when combined with Lopinavir.	Approved
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Lopinavir.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Lopinavir is combined with Pethidine.	Approved
Phenacetin	The metabolism of Phenacetin can be decreased when combined with Lopinavir.	Withdrawn
Phenformin	The metabolism of Phenformin can be decreased when combined with Lopinavir.	Approved, Investigational, Withdrawn
Pheniramine	The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Lopinavir.	Approved
Phenobarbital	The serum concentration of Lopinavir can be decreased when it is combined with Phenobarbital.	Approved, Investigational
Phenoxybenzamine	The metabolism of Phenoxybenzamine can be decreased when combined with Lopinavir.	Approved
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Lopinavir.	Approved, Investigational
Phenytoin	The serum concentration of Lopinavir can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Pilocarpine	The metabolism of Pilocarpine can be decreased when combined with Lopinavir.	Approved, Investigational
Pimecrolimus	The metabolism of Pimecrolimus can be decreased when combined with Lopinavir.	Approved, Investigational
Pimozide	The serum concentration of Pimozide can be increased when it is combined with Lopinavir.	Approved
Pinacidil	The metabolism of Pinacidil can be decreased when combined with Lopinavir.	Approved
Pinaverium	The metabolism of Pinaverium can be decreased when combined with Lopinavir.	Approved
Pindolol	The metabolism of Pindolol can be decreased when combined with Lopinavir.	Approved, Investigational
Pioglitazone	The metabolism of Pioglitazone can be decreased when combined with Lopinavir.	Approved, Investigational
Piperaquine	The metabolism of Piperaquine can be decreased when combined with Lopinavir.	Approved, Investigational
Piperazine	The metabolism of Piperazine can be decreased when combined with Lopinavir.	Approved, Vet Approved
Pipotiazine	The metabolism of Pipotiazine can be decreased when combined with Lopinavir.	Approved, Investigational
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Lopinavir.	Approved
Pitolisant	The serum concentration of Pitolisant can be increased when it is combined with Lopinavir.	Approved, Investigational
Podofilox	The metabolism of Podofilox can be decreased when combined with Lopinavir.	Approved
Pomalidomide	The metabolism of Pomalidomide can be decreased when combined with Lopinavir.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Lopinavir.	Approved, Investigational
Posaconazole	The metabolism of Lopinavir can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Lopinavir.	Approved, Investigational
Pranlukast	The serum concentration of Pranlukast can be increased when it is combined with Lopinavir.	Approved, Investigational
Prasterone	The metabolism of Prasterone can be decreased when combined with Lopinavir.	Approved, Investigational, Nutraceutical
Prasterone sulfate	The serum concentration of Prasterone sulfate can be increased when it is combined with Lopinavir.	Investigational
Prasugrel	The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Lopinavir resulting in a loss in efficacy.	Approved
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Lopinavir.	Approved
Prazepam	The metabolism of Prazepam can be decreased when combined with Lopinavir.	Approved, Illicit
Praziquantel	The metabolism of Praziquantel can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Prednicarbate	The serum concentration of Prednicarbate can be increased when it is combined with Lopinavir.	Approved, Investigational
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Lopinavir.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be increased when it is combined with Lopinavir.	Approved, Vet Approved
Pregabalin	The metabolism of Pregabalin can be decreased when combined with Lopinavir.	Approved, Illicit, Investigational
Pregnenolone	The serum concentration of Pregnenolone can be increased when it is combined with Lopinavir.	Approved, Experimental, Investigational
Prenylamine	The metabolism of Prenylamine can be decreased when combined with Lopinavir.	Withdrawn
Primaquine	Primaquine may increase the QTc-prolonging activities of Lopinavir.	Approved
Primidone	The serum concentration of Primidone can be increased when it is combined with Lopinavir.	Approved, Vet Approved
Procainamide	The risk or severity of QTc prolongation can be increased when Procainamide is combined with Lopinavir.	Approved
Prochlorperazine	The metabolism of Prochlorperazine can be decreased when combined with Lopinavir.	Approved, Vet Approved
Progesterone	The metabolism of Progesterone can be decreased when combined with Lopinavir.	Approved, Vet Approved
Proguanil	The metabolism of Proguanil can be decreased when combined with Lopinavir.	Approved
Promazine	Promazine may increase the QTc-prolonging activities of Lopinavir.	Approved, Vet Approved
Promethazine	The risk or severity of QTc prolongation can be increased when Promethazine is combined with Lopinavir.	Approved, Investigational
Propafenone	The serum concentration of Lopinavir can be increased when it is combined with Propafenone.	Approved
Propiverine	The metabolism of Propiverine can be decreased when combined with Lopinavir.	Approved, Investigational
Propofol	The metabolism of Propofol can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Propranolol	The metabolism of Propranolol can be decreased when combined with Lopinavir.	Approved, Investigational
Protriptyline	The metabolism of Protriptyline can be decreased when combined with Lopinavir.	Approved
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Lopinavir.	Approved
Pyrazinamide	The metabolism of Pyrazinamide can be decreased when combined with Lopinavir.	Approved, Investigational
Quazepam	The metabolism of Quazepam can be decreased when combined with Lopinavir.	Approved, Illicit
Quetiapine	The serum concentration of Quetiapine can be increased when it is combined with Lopinavir.	Approved
Quinacrine	The metabolism of Quinacrine can be decreased when combined with Lopinavir.	Approved, Investigational
Quingestanol	The serum concentration of Quingestanol can be decreased when it is combined with Lopinavir.	Experimental
Quinidine	Lopinavir may increase the QTc-prolonging activities of Quinidine.	Approved, Investigational
Quinine	The serum concentration of Quinine can be decreased when it is combined with Lopinavir.	Approved
Rabeprazole	The metabolism of Rabeprazole can be decreased when combined with Lopinavir.	Approved, Investigational
Raloxifene	The metabolism of Raloxifene can be decreased when combined with Lopinavir.	Approved, Investigational
Ramelteon	The serum concentration of Ramelteon can be increased when it is combined with Lopinavir.	Approved, Investigational
Ranitidine	The serum concentration of Ranitidine can be increased when it is combined with Lopinavir.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Lopinavir.	Approved, Investigational
Reboxetine	The metabolism of Reboxetine can be decreased when combined with Lopinavir.	Approved, Investigational
Regorafenib	The metabolism of Regorafenib can be decreased when combined with Lopinavir.	Approved
Remoxipride	The metabolism of Remoxipride can be decreased when combined with Lopinavir.	Approved, Withdrawn
Repaglinide	The serum concentration of Repaglinide can be increased when it is combined with Lopinavir.	Approved, Investigational
Repinotan	The metabolism of Repinotan can be decreased when combined with Lopinavir.	Investigational
Retapamulin	The serum concentration of Retapamulin can be increased when it is combined with Lopinavir.	Approved
Ribociclib	The serum concentration of Ribociclib can be increased when it is combined with Lopinavir.	Approved, Investigational
Rifabutin	The serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Lopinavir.	Approved, Investigational
Rifampicin	The risk or severity of adverse effects can be increased when Rifampicin is combined with Lopinavir.	Approved
Rifapentine	The serum concentration of Rifapentine can be increased when it is combined with Lopinavir.	Approved, Investigational
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Lopinavir.	Approved, Investigational
Rilpivirine	The serum concentration of Rilpivirine can be increased when it is combined with Lopinavir.	Approved
Rimexolone	The serum concentration of Rimexolone can be increased when it is combined with Lopinavir.	Approved
Rimonabant	The metabolism of Rimonabant can be decreased when combined with Lopinavir.	Approved, Investigational
Riociguat	The serum concentration of Riociguat can be increased when it is combined with Lopinavir.	Approved
Risperidone	The metabolism of Risperidone can be decreased when combined with Lopinavir.	Approved, Investigational
Ritonavir	The metabolism of Ritonavir can be decreased when combined with Lopinavir.	Approved, Investigational
Rivaroxaban	The metabolism of Rivaroxaban can be decreased when combined with Lopinavir.	Approved
Rofecoxib	The metabolism of Rofecoxib can be decreased when combined with Lopinavir.	Approved, Investigational, Withdrawn
Rolapitant	The metabolism of Rolapitant can be decreased when combined with Lopinavir.	Approved, Investigational
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Lopinavir.	Approved, Investigational
Ropinirole	The metabolism of Ropinirole can be decreased when combined with Lopinavir.	Approved, Investigational
Ropivacaine	The metabolism of Ropivacaine can be decreased when combined with Lopinavir.	Approved
Rosiglitazone	The metabolism of Rosiglitazone can be decreased when combined with Lopinavir.	Approved, Investigational
Rosuvastatin	The metabolism of Rosuvastatin can be decreased when combined with Lopinavir.	Approved
Rotigotine	The metabolism of Rotigotine can be decreased when combined with Lopinavir.	Approved
Roxithromycin	The metabolism of Roxithromycin can be decreased when combined with Lopinavir.	Approved, Investigational, Withdrawn
Rucaparib	The metabolism of Rucaparib can be decreased when combined with Lopinavir.	Approved, Investigational
Rupatadine	The metabolism of Rupatadine can be decreased when combined with Lopinavir.	Approved
Ruxolitinib	The serum concentration of Ruxolitinib can be increased when it is combined with Lopinavir.	Approved
Safinamide	The metabolism of Safinamide can be decreased when combined with Lopinavir.	Approved, Investigational
Salbutamol	The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Lopinavir.	Approved, Vet Approved
Salmeterol	The serum concentration of Salmeterol can be increased when it is combined with Lopinavir.	Approved
Saquinavir	Saquinavir may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Sarilumab	The therapeutic efficacy of Lopinavir can be decreased when used in combination with Sarilumab.	Approved, Investigational
Saxagliptin	The serum concentration of Saxagliptin can be increased when it is combined with Lopinavir.	Approved
Selegiline	The metabolism of Selegiline can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Seletracetam	The metabolism of Seletracetam can be decreased when combined with Lopinavir.	Investigational
Selexipag	The metabolism of Selexipag can be decreased when combined with Lopinavir.	Approved
Seratrodast	The metabolism of Seratrodast can be decreased when combined with Lopinavir.	Approved
Sertindole	The metabolism of Sertindole can be decreased when combined with Lopinavir.	Approved, Investigational, Withdrawn
Sertraline	The metabolism of Sertraline can be decreased when combined with Lopinavir.	Approved
Sevoflurane	The metabolism of Sevoflurane can be decreased when combined with Lopinavir.	Approved, Vet Approved
Sibutramine	The metabolism of Sibutramine can be decreased when combined with Lopinavir.	Approved, Illicit, Investigational, Withdrawn
Sildenafil	The serum concentration of Sildenafil can be increased when it is combined with Lopinavir.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Lopinavir.	Approved
Siltuximab	The serum concentration of Lopinavir can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Simeprevir can be increased when it is combined with Lopinavir.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Lopinavir.	Approved
Sirolimus	The metabolism of Sirolimus can be decreased when combined with Lopinavir.	Approved, Investigational
Sitagliptin	The metabolism of Sitagliptin can be decreased when combined with Lopinavir.	Approved, Investigational
Solifenacin	The metabolism of Solifenacin can be decreased when combined with Lopinavir.	Approved
Sonidegib	The serum concentration of Sonidegib can be increased when it is combined with Lopinavir.	Approved, Investigational
Sorafenib	The serum concentration of Sorafenib can be increased when it is combined with Lopinavir.	Approved, Investigational
Sotagliflozin	The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Lopinavir.	Investigational
Sotalol	The risk or severity of QTc prolongation can be increased when Sotalol is combined with Lopinavir.	Approved
Sparteine	The metabolism of Sparteine can be decreased when combined with Lopinavir.	Experimental
Spiramycin	The metabolism of Spiramycin can be decreased when combined with Lopinavir.	Approved
St. John's Wort	The metabolism of Lopinavir can be increased when combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stiripentol	The serum concentration of Lopinavir can be increased when it is combined with Stiripentol.	Approved
Sufentanil	The metabolism of Sufentanil can be decreased when combined with Lopinavir.	Approved, Investigational
Sulfadiazine	The metabolism of Sulfadiazine can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Sulfamethoxazole	The metabolism of Sulfamethoxazole can be decreased when combined with Lopinavir.	Approved
Sulfinpyrazone	The metabolism of Sulfinpyrazone can be decreased when combined with Lopinavir.	Approved
Sulfisoxazole	Sulfisoxazole may increase the QTc-prolonging activities of Lopinavir.	Approved, Vet Approved
Sulodexide	The therapeutic efficacy of Sulodexide can be decreased when used in combination with Lopinavir.	Approved, Investigational
Sumatriptan	The serum concentration of Sumatriptan can be increased when it is combined with Lopinavir.	Approved, Investigational
Sunitinib	The metabolism of Sunitinib can be decreased when combined with Lopinavir.	Approved, Investigational
Suvorexant	The serum concentration of Suvorexant can be increased when it is combined with Lopinavir.	Approved, Investigational
Synthetic Conjugated Estrogens, A	The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Lopinavir.	Approved
Synthetic Conjugated Estrogens, B	The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Lopinavir.	Approved
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Lopinavir.	Approved, Investigational
Tadalafil	The serum concentration of Tadalafil can be increased when it is combined with Lopinavir.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be increased when it is combined with Lopinavir.	Approved
Tamsulosin	The serum concentration of Tamsulosin can be increased when it is combined with Lopinavir.	Approved, Investigational
Tapentadol	The metabolism of Tapentadol can be decreased when combined with Lopinavir.	Approved
Tasimelteon	The serum concentration of Tasimelteon can be increased when it is combined with Lopinavir.	Approved, Investigational
Tasosartan	The metabolism of Tasosartan can be decreased when combined with Lopinavir.	Approved
Taurochenodeoxycholic acid	The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Lopinavir.	Experimental
Tegaserod	The metabolism of Tegaserod can be decreased when combined with Lopinavir.	Approved, Investigational, Withdrawn
Telaprevir	The serum concentration of Telaprevir can be decreased when it is combined with Lopinavir.	Approved, Withdrawn
Telavancin	Telavancin may increase the QTc-prolonging activities of Lopinavir.	Approved
Telithromycin	Telithromycin may increase the QTc-prolonging activities of Lopinavir.	Approved
Temazepam	The metabolism of Temazepam can be decreased when combined with Lopinavir.	Approved, Investigational
Temsirolimus	The risk or severity of adverse effects can be increased when Lopinavir is combined with Temsirolimus.	Approved
Teniposide	The metabolism of Teniposide can be decreased when combined with Lopinavir.	Approved
Tenofovir disoproxil	Lopinavir may increase the nephrotoxic activities of Tenofovir disoproxil.	Approved, Investigational
Terbinafine	The metabolism of Terbinafine can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Terbutaline	Terbutaline may increase the QTc-prolonging activities of Lopinavir.	Approved
Terfenadine	The serum concentration of Terfenadine can be increased when it is combined with Lopinavir.	Approved, Withdrawn
Terguride	The risk or severity of adverse effects can be increased when Terguride is combined with Lopinavir.	Experimental
Terodiline	The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Terodiline.	Experimental
Tesmilifene	The metabolism of Tesmilifene can be decreased when combined with Lopinavir.	Investigational
Testosterone	The metabolism of Testosterone can be decreased when combined with Lopinavir.	Approved, Investigational
Testosterone cypionate	The metabolism of Testosterone cypionate can be decreased when combined with Lopinavir.	Approved
Testosterone enanthate	The metabolism of Testosterone enanthate can be decreased when combined with Lopinavir.	Approved
Testosterone propionate	The metabolism of Testosterone propionate can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoate	The metabolism of Testosterone undecanoate can be decreased when combined with Lopinavir.	Approved, Investigational
Tetrabenazine	The serum concentration of Tetrabenazine can be increased when it is combined with Lopinavir.	Approved, Investigational
Tetracycline	The metabolism of Tetracycline can be decreased when combined with Lopinavir.	Approved, Vet Approved
Tetrahydropalmatine	The metabolism of Tetrahydropalmatine can be decreased when combined with Lopinavir.	Investigational
Tetrandrine	The metabolism of Tetrandrine can be decreased when combined with Lopinavir.	Experimental
Tezacaftor	The metabolism of Tezacaftor can be decreased when combined with Lopinavir.	Approved, Investigational
Thalidomide	The metabolism of Thalidomide can be increased when combined with Lopinavir.	Approved, Investigational, Withdrawn
Theophylline	The metabolism of Theophylline can be decreased when combined with Lopinavir.	Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Lopinavir.	Approved, Withdrawn
Thiotepa	The metabolism of Thiotepa can be decreased when combined with Lopinavir.	Approved, Investigational
Thiothixene	Thiothixene may increase the QTc-prolonging activities of Lopinavir.	Approved
Tiagabine	The metabolism of Tiagabine can be decreased when combined with Lopinavir.	Approved, Investigational
Tianeptine	The serum concentration of Tianeptine can be increased when it is combined with Lopinavir.	Approved, Investigational
Ticagrelor	The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Lopinavir resulting in a loss in efficacy.	Approved
Ticlopidine	The metabolism of Ticlopidine can be decreased when combined with Lopinavir.	Approved
Timolol	The metabolism of Timolol can be decreased when combined with Lopinavir.	Approved
Tinidazole	The metabolism of Tinidazole can be decreased when combined with Lopinavir.	Approved, Investigational
Tiotropium	The metabolism of Tiotropium can be decreased when combined with Lopinavir.	Approved
Tipranavir	The serum concentration of Lopinavir can be decreased when it is combined with Tipranavir.	Approved, Investigational
Tixocortol	The serum concentration of Tixocortol can be increased when it is combined with Lopinavir.	Approved, Withdrawn
Tizanidine	Tizanidine may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Tocilizumab	The serum concentration of Lopinavir can be decreased when it is combined with Tocilizumab.	Approved
Tocofersolan	The metabolism of Tocofersolan can be decreased when combined with Lopinavir.	Approved
Tocopherol	The metabolism of Tocopherol can be decreased when combined with Lopinavir.	Approved, Investigational
Tofacitinib	The serum concentration of Tofacitinib can be increased when it is combined with Lopinavir.	Approved, Investigational
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Lopinavir.	Approved, Investigational
Tolbutamide	The metabolism of Tolbutamide can be increased when combined with Lopinavir.	Approved, Investigational
Tolfenamic Acid	The metabolism of Tolfenamic Acid can be decreased when combined with Lopinavir.	Approved, Investigational
Tolterodine	The serum concentration of Tolterodine can be increased when it is combined with Lopinavir.	Approved, Investigational
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Lopinavir.	Approved
Topiramate	The serum concentration of Topiramate can be increased when it is combined with Lopinavir.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Lopinavir.	Approved, Investigational
Toremifene	The risk or severity of adverse effects can be increased when Lopinavir is combined with Toremifene.	Approved, Investigational
Trabectedin	The serum concentration of Trabectedin can be increased when it is combined with Lopinavir.	Approved, Investigational
Tramadol	The therapeutic efficacy of Tramadol can be decreased when used in combination with Lopinavir.	Approved, Investigational
Tranilast	The metabolism of Tranilast can be decreased when combined with Lopinavir.	Approved, Investigational
Trastuzumab emtansine	The serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Lopinavir.	Approved, Investigational
Trazodone	Lopinavir may increase the QTc-prolonging activities of Trazodone.	Approved, Investigational
Treprostinil	Treprostinil may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Tretinoin	The metabolism of Tretinoin can be decreased when combined with Lopinavir.	Approved, Investigational, Nutraceutical
Triamcinolone	The metabolism of Triamcinolone can be decreased when combined with Lopinavir.	Approved, Vet Approved
Triazolam	The serum concentration of Triazolam can be increased when it is combined with Lopinavir.	Approved, Investigational
Trimebutine	The metabolism of Trimebutine can be decreased when combined with Lopinavir.	Approved
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Lopinavir.	Approved
Trimethoprim	The metabolism of Trimethoprim can be decreased when combined with Lopinavir.	Approved, Vet Approved
Trimipramine	The metabolism of Trimipramine can be decreased when combined with Lopinavir.	Approved
Triptorelin	Triptorelin may increase the QTc-prolonging activities of Lopinavir.	Approved, Vet Approved
Troglitazone	The metabolism of Troglitazone can be decreased when combined with Lopinavir.	Investigational, Withdrawn
Troleandomycin	The metabolism of Troleandomycin can be decreased when combined with Lopinavir.	Approved
Udenafil	The metabolism of Udenafil can be decreased when combined with Lopinavir.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Lopinavir.	Approved
Ulobetasol	The serum concentration of Ulobetasol can be increased when it is combined with Lopinavir.	Approved
Umeclidinium	The metabolism of Umeclidinium can be decreased when combined with Lopinavir.	Approved
Valbenazine	The metabolism of Valbenazine can be decreased when combined with Lopinavir.	Approved, Investigational
Valdecoxib	The metabolism of Valdecoxib can be decreased when combined with Lopinavir.	Approved, Investigational, Withdrawn
Valproic Acid	The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Valproic Acid.	Approved, Investigational
Vandetanib	The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Vandetanib.	Approved
Vanoxerine	The metabolism of Vanoxerine can be decreased when combined with Lopinavir.	Investigational
Vardenafil	The serum concentration of Vardenafil can be increased when it is combined with Lopinavir.	Approved
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Lopinavir.	Approved
Velpatasvir	The metabolism of Velpatasvir can be decreased when combined with Lopinavir.	Approved, Investigational
Vemurafenib	The serum concentration of Lopinavir can be decreased when it is combined with Vemurafenib.	Approved
Venetoclax	The metabolism of Venetoclax can be decreased when combined with Lopinavir.	Approved, Investigational
Venlafaxine	The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Lopinavir.	Approved
Verapamil	The metabolism of Verapamil can be decreased when combined with Lopinavir.	Approved
Vernakalant	The metabolism of Vernakalant can be decreased when combined with Lopinavir.	Approved, Investigational
Vicriviroc	The metabolism of Vicriviroc can be decreased when combined with Lopinavir.	Investigational
Vilanterol	The metabolism of Vilanterol can be decreased when combined with Lopinavir.	Approved
Vilazodone	The serum concentration of Vilazodone can be increased when it is combined with Lopinavir.	Approved
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lopinavir.	Approved, Investigational
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Lopinavir.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Lopinavir.	Approved, Investigational
Vindesine	The serum concentration of Vindesine can be increased when it is combined with Lopinavir.	Approved, Investigational
Vinflunine	The metabolism of Vinflunine can be decreased when combined with Lopinavir.	Approved, Investigational
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Lopinavir.	Approved, Investigational
Vinpocetine	The metabolism of Vinpocetine can be decreased when combined with Lopinavir.	Investigational
Vismodegib	The metabolism of Vismodegib can be decreased when combined with Lopinavir.	Approved, Investigational
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Lopinavir.	Approved, Investigational
Vorapaxar	The serum concentration of Vorapaxar can be increased when it is combined with Lopinavir.	Approved
Voriconazole	The serum concentration of Voriconazole can be decreased when it is combined with Lopinavir.	Approved, Investigational
Vorinostat	Vorinostat may increase the QTc-prolonging activities of Lopinavir.	Approved, Investigational
Vortioxetine	The serum concentration of Vortioxetine can be increased when it is combined with Lopinavir.	Approved, Investigational
Voxilaprevir	The metabolism of Voxilaprevir can be decreased when combined with Lopinavir.	Approved, Investigational
Warfarin	The serum concentration of Warfarin can be decreased when it is combined with Lopinavir.	Approved
WIN 55212-2	The metabolism of WIN 55212-2 can be decreased when combined with Lopinavir.	Experimental
Yohimbine	The metabolism of Yohimbine can be decreased when combined with Lopinavir.	Approved, Investigational, Vet Approved
Zafirlukast	The metabolism of Zafirlukast can be decreased when combined with Lopinavir.	Approved, Investigational
Zalcitabine	The metabolism of Zalcitabine can be decreased when combined with Lopinavir.	Approved, Investigational
Zaleplon	The metabolism of Zaleplon can be decreased when combined with Lopinavir.	Approved, Illicit, Investigational
Ziconotide	The metabolism of Ziconotide can be decreased when combined with Lopinavir.	Approved
Zidovudine	The metabolism of Zidovudine can be decreased when combined with Lopinavir.	Approved
Zileuton	The metabolism of Zileuton can be decreased when combined with Lopinavir.	Approved, Investigational, Withdrawn
Ziprasidone	The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Lopinavir.	Approved
Zolpidem	The metabolism of Zolpidem can be decreased when combined with Lopinavir.	Approved
Zomepirac	The metabolism of Zomepirac can be decreased when combined with Lopinavir.	Withdrawn
Zonisamide	The metabolism of Zonisamide can be decreased when combined with Lopinavir.	Approved, Investigational
Zopiclone	The serum concentration of Zopiclone can be increased when it is combined with Lopinavir.	Approved
Zotepine	The metabolism of Zotepine can be decreased when combined with Lopinavir.	Approved, Investigational, Withdrawn
Zuclopenthixol	The serum concentration of Zuclopenthixol can be increased when it is combined with Lopinavir.	Approved, Investigational

Food Interactions

• Avoid St.John's Wort.
• Take with food.

References

Synthesis Reference

US5914332

General References

Not Available

External Links

Human Metabolome Database

HMDB0015539

KEGG Drug

D01425

KEGG Compound

C12871

PubChem Compound

92727

PubChem Substance

46508588

ChemSpider

83706

BindingDB

578

ChEBI

31781

ChEMBL

CHEMBL729

Therapeutic Targets Database

DAP000708

PharmGKB

PA450264

HET

AB1

RxList

RxList Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Lopinavir

ATC Codes

J05AR10 — Lopinavir and ritonavir

• J05AR — Antivirals for treatment of HIV infections, combinations
• J05A — DIRECT ACTING ANTIVIRALS
• J05 — ANTIVIRALS FOR SYSTEMIC USE
• J — ANTIINFECTIVES FOR SYSTEMIC USE

PDB Entries

1mui / 1rv7 / 2o4s / 2q5k / 2qhc / 2rkf / 2rkg / 2z54 / 3ogq / 4l1a

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Completed	Other	Healthy Volunteers	1
0	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Plasmodium Infections	1
1	Completed	Not Available	Healthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Lopinavir/Ritonavir	1
1	Completed	Not Available	Hepatitis C Viral Infection	1
1	Completed	Basic Science	Healthy Volunteers	1
1	Completed	Basic Science	Healthy Volunteers / Human Immunodeficiency Virus (HIV) Infections	1
1	Completed	Other	Drug-induced QT Interval Prolongation / Pharmacodynamics / Pharmacokinetics	1
1	Completed	Other	Fenofibrate / Glucuronosyltransferase / Human Immunodeficiency Virus (HIV) / Hypertriglyceridemias / Protease Inhibitors	1
1	Completed	Treatment	Acquired Immune Deficiency Syndrome (AIDS)	1
1	Completed	Treatment	Healthy Volunteers	1
1	Completed	Treatment	Healthy Volunteers / Human Immunodeficiency Virus (HIV) Infections	1
1	Completed	Treatment	Hepatitis C Viral Infection / Thrombocytopenias	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV)	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	5
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Plasmodium Infections	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) / Pregnancy	1
1	Completed	Treatment	Insulin Resistance	1
1	Completed	Treatment	Tuberculosis	1
1	Suspended	Treatment	Human Immunodeficiency Virus (HIV)	1
1	Terminated	Treatment	Human Immunodeficiency Virus (HIV) / Tuberculosis	1
1, 2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	2
1, 2	Completed	Treatment	Infection, Human Immunodeficiency Virus I / Pf Subclinical Parasitemia	1
2	Active Not Recruiting	Treatment	Human Immunodeficiency Virus (HIV) Infections	2
2	Completed	Not Available	Human Immunodeficiency Virus (HIV) Infections / Tuberculosis	1
2	Completed	Prevention	Human Immunodeficiency Virus (HIV) Infections	1
2	Completed	Prevention	Human Immunodeficiency Virus (HIV) Infections / Pregnancy	1
2	Completed	Treatment	Fibrosis, Liver / Hepatitis C Viral Infection / Human Immunodeficiency Virus (HIV)	1
2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	20
2	Recruiting	Other	Human Immunodeficiency Virus (HIV) / Tuberculosis	1
2	Terminated	Treatment	Anaplastic Astrocytoma (AA) / Anaplastic Ependymoma / Anaplastic Oligodendroglioma (AO) / Brain Stem Gliomas / Giant Cell Glioblastoma / Glioblastomas / Gliosarcoma / Mixed Gliomas / Neoplasms, Brain	1
2	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
2	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I	1
2	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections / Tuberculosis	1
2	Unknown Status	Prevention	Human Immunodeficiency Virus (HIV) / Viral Hepatitis B	1
2	Unknown Status	Treatment	Human Immunodeficiency Virus (HIV) Infections	2
2	Withdrawn	Treatment	Hepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections	1
2, 3	Completed	Treatment	Acute HIV Infection	1
2, 3	Completed	Treatment	Human Immunodeficiency Virus (HIV)	1
2, 3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	4
2, 3	Recruiting	Treatment	Human Immunodeficiency Virus (HIV) / Pediatric AIDS	1
2, 3	Recruiting	Treatment	Human Immunodeficiency Virus (HIV) / Pregnancy	1
3	Active Not Recruiting	Treatment	Acute HIV Infection	1
3	Active Not Recruiting	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
3	Completed	Not Available	Human Immunodeficiency Virus (HIV) Infections	1
3	Completed	Prevention	Human Immunodeficiency Virus (HIV) Infections	4
3	Completed	Prevention	Human Immunodeficiency Virus (HIV) Infections / Plasmodium Infections	1
3	Completed	Treatment	Acquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections	1
3	Completed	Treatment	HIV-Infected Children	1
3	Completed	Treatment	Human Immunodeficiency Virus (HIV)	3
3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	23
3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)	1
3	Completed	Treatment	Human Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections	1
3	Completed	Treatment	Infection, Human Immunodeficiency Virus I	2
3	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections	2
3	Terminated	Treatment	Human Immunodeficiency Virus Type 1 (HIV-1)	1
3	Unknown Status	Treatment	Acquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections	1
3	Unknown Status	Treatment	Hepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections	2
3	Unknown Status	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
3	Withdrawn	Treatment	Human Immunodeficiency Virus (HIV)	1
4	Completed	Not Available	Healthy Volunteers	1
4	Completed	Not Available	Human Immunodeficiency Virus (HIV) Infections / Tuberculosis	1
4	Completed	Not Available	Human Immunodeficiency Virus (HIV) / Proteinuria	1
4	Completed	Basic Science	Cardiovascular Disease (CVD) / Dyslipidemias / Glucose Metabolism Disorders / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies / Metabolic Diseases	1
4	Completed	Basic Science	Human Immunodeficiency Virus (HIV) Infections	1
4	Completed	Diagnostic	AIDS-Related Opportunistic Infections / Human Immunodeficiency Virus (HIV) Infections	1
4	Completed	Prevention	Human Immunodeficiency Virus (HIV)	1
4	Completed	Prevention	Human Immunodeficiency Virus (HIV) Infections	3
4	Completed	Prevention	Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies	1
4	Completed	Prevention	Human Immunodeficiency Virus (HIV) Infections / Pregnancy	1
4	Completed	Treatment	Acquired Immune Deficiency Syndrome (AIDS) / Tuberculosis	1
4	Completed	Treatment	HIV/AIDS Treatment / Human Immunodeficiency Virus (HIV) Infections	1
4	Completed	Treatment	HIV/HCV Co-infection / Human Immunodeficiency Virus (HIV) Infections	1
4	Completed	Treatment	Healthy Volunteers	1
4	Completed	Treatment	Hiv-positive / Malnourished	1
4	Completed	Treatment	Human Immunodeficiency Virus (HIV)	8
4	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	13
4	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Lipoatrophy	1
4	Completed	Treatment	Human Immunodeficiency Virus (HIV) / Mitochondrial Toxicity	1
4	Completed	Treatment	Human Immunodeficiency Virus (HIV) / Tuberculosis	1
4	Completed	Treatment	Human Immunodeficiency Virus Type 1 (HIV-1)	2
4	Recruiting	Prevention	HIV/AIDS and Infections	1
4	Recruiting	Treatment	Acquired Immune Deficiency Syndrome (AIDS) / Tuberculosis	1
4	Recruiting	Treatment	Human Immunodeficiency Virus (HIV)	1
4	Recruiting	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
4	Terminated	Not Available	Human Immunodeficiency Virus (HIV) Infections	2
4	Terminated	Treatment	Acquired Immune Deficiency Syndrome (AIDS)	1
4	Terminated	Treatment	Acquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections	1
4	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections	7
4	Unknown Status	Prevention	HIV-Associated Lipodystrophy Syndrome / Human Immunodeficiency Virus (HIV) Infections	1
4	Unknown Status	Treatment	Acquired Immune Deficiency Syndrome (AIDS)	1
4	Unknown Status	Treatment	Acquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections	1
4	Unknown Status	Treatment	Human Immunodeficiency Virus (HIV) Infections	4
4	Unknown Status	Treatment	Human Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Completed	Not Available	Healthy Volunteers	1
Not Available	Completed	Not Available	Human Immunodeficiency Virus (HIV)	3
Not Available	Completed	Not Available	Human Immunodeficiency Virus (HIV) Infections	6
Not Available	Completed	Not Available	Infection, Human Immunodeficiency Virus I	3
Not Available	Completed	Basic Science	Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Completed	Other	Endothelial Dysfunction	1
Not Available	Completed	Prevention	Human Immunodeficiency Virus (HIV)	1
Not Available	Completed	Prevention	Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Completed	Treatment	Hepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	12
Not Available	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies / Wasting Disease	1
Not Available	Completed	Treatment	Primary Biliary Cirrhosis (PBC)	1
Not Available	Recruiting	Not Available	Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)	1
Not Available	Terminated	Treatment	Human Immunodeficiency Virus (HIV)	1
Not Available	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Unknown Status	Basic Science	Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Unknown Status	Treatment	AIDS/HIV PROBLEM	1
Not Available	Unknown Status	Treatment	Acquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV)	1
Not Available	Withdrawn	Treatment	Hepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Withdrawn	Treatment	Lymphoma, Hodgkins / Stage I Adult Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Capsule	Oral
Solution	Oral
Tablet	Oral
Tablet, film coated	Oral

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US6703403	Yes	1996-12-26	2016-12-26
US6037157	Yes	1996-12-26	2016-12-26
US6232333	Yes	1998-05-07	2018-05-07
US7432294	Yes	2000-11-22	2020-11-22
US7141593	Yes	2000-11-22	2020-11-22
US5914332	Yes	1996-06-13	2016-06-13
US6284767	Yes	1996-08-15	2016-08-15
US7364752	Yes	2001-05-10	2021-05-10
US8309613	Yes	2005-06-24	2025-06-24
US8377952	Yes	2008-04-22	2028-04-22
US8691878	Yes	2005-02-25	2025-02-25
US8025899	Yes	2008-06-14	2028-06-14
US7148359	Yes	2000-01-19	2020-01-19
US8470347	Yes	2007-03-17	2027-03-17
US8268349	Yes	2005-02-25	2025-02-25
US8399015	Yes	2005-02-25	2025-02-25
US6458818	Yes	1998-05-07	2018-05-07
US6521651	Yes	1998-05-07	2018-05-07
US6911214	Yes	2002-05-28	2022-05-28
US8501219	No	2001-11-28	2021-11-28

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00192 mg/mL	ALOGPS
logP	3.91	ALOGPS
logP	4.69	ChemAxon
logS	-5.5	ALOGPS
pKa (Strongest Acidic)	13.39	ChemAxon
pKa (Strongest Basic)	-1.5	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	120 Å2	ChemAxon
Rotatable Bond Count	15	ChemAxon
Refractivity	179.36 m3·mol-1	ChemAxon
Polarizability	69.2 Å3	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	-	0.6593
Blood Brain Barrier	-	0.9916
Caco-2 permeable	+	0.8856
P-glycoprotein substrate	Substrate	0.8755
P-glycoprotein inhibitor I	Inhibitor	0.7355
P-glycoprotein inhibitor II	Inhibitor	0.5277
Renal organic cation transporter	Non-inhibitor	0.8578
CYP450 2C9 substrate	Non-substrate	0.7508
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Substrate	0.6732
CYP450 1A2 substrate	Non-inhibitor	0.8935
CYP450 2C9 inhibitor	Non-inhibitor	0.7326
CYP450 2D6 inhibitor	Non-inhibitor	0.9438
CYP450 2C19 inhibitor	Non-inhibitor	0.7983
CYP450 3A4 inhibitor	Non-inhibitor	0.6469
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9054
Ames test	Non AMES toxic	0.8049
Carcinogenicity	Non-carcinogens	0.7865
Biodegradation	Not ready biodegradable	0.9182
Rat acute toxicity	2.2503 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8605
hERG inhibition (predictor II)	Inhibitor	0.8475

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0fb9-0119005000-e99616dc321beea979ae
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0532-1900601000-f85a252f1640f27563a8

Taxonomy

Description

This compound belongs to the class of organic compounds known as valine and derivatives. These are compounds containing valine or a derivative thereof resulting from reaction of valine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Valine and derivatives

Alternative Parents

Amphetamines and derivatives / m-Xylenes / Phenol ethers / Phenoxy compounds / Alkyl aryl ethers / Pyrimidones / Diazinanes / N-acyl amines / Secondary carboxylic acid amides / UreasSecondary alcohols / Azacyclic compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Organopnictogen compounds

show 7 more

Substituents

Valine or derivatives / Amphetamine or derivatives / Phenoxy compound / Phenol ether / M-xylene / Xylene / Alkyl aryl ether / Pyrimidone / Monocyclic benzene moiety / 1,3-diazinaneFatty amide / Fatty acyl / N-acyl-amine / Benzenoid / Pyrimidine / Secondary alcohol / Secondary carboxylic acid amide / Urea / Carboxamide group / Carbonic acid derivative / Ether / Azacycle / Organoheterocyclic compound / Organic nitrogen compound / Alcohol / Hydrocarbon derivative / Organic oxide / Carbonyl group / Organopnictogen compound / Organic oxygen compound / Organooxygen compound / Organonitrogen compound / Aromatic heteromonocyclic compound

show 23 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

dicarboxylic acid diamide, amphetamines (CHEBI:31781)

Drug created on August 29, 2007 12:45 / Updated on August 15, 2018 09:51